inn,title,setid,published,route,ph,ph_is_range,buffer_species,buffer_conc_mm,surfactant,surfactant_pct_wv,protein_conc_mg_ml,label_mw_kda,fill_volume_ml,n_ingredients_parsed,source_text,fv_pi,fv_mw_kda,fv_gravy,fv_aromaticity,fv_instability,fv_charge_ph5,fv_charge_ph6,fv_charge_ph7,fv_hydrophobic_frac,isotype,light_chain,target,format
adalimumab,"HYRIMOZ (ADALIMUMAB-ADAZ) INJECTION, SOLUTION HYRIMOZ (ADALIMUMAB-ADAZ) KIT [SANDOZ INC]",1ac7d061-3380-468c-b077-c05f8dfbc829,"Aug 19, 2026",subcutaneous,5.2,False,,,polysorbate 80,0.04,,148.0,0.8,3.0,"Each 0.8 mL of HYRIMOZ contains adalimumab-adaz (80 mg), adipic acid (1.75 mg), mannitol (33.6 mg), polysorbate 80 (0.32 mg), and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
adalimumab,"HYRIMOZ (ADALIMUMAB-ADAZ) INJECTION, SOLUTION HYRIMOZ (ADALIMUMAB-ADAZ) KIT [SANDOZ INC]",1ac7d061-3380-468c-b077-c05f8dfbc829,"Aug 19, 2026",subcutaneous,5.2,False,,,polysorbate 80,0.04,,148.0,0.4,3.0,"Each 0.4 mL of HYRIMOZ contains adalimumab-adaz (40 mg), adipic acid (0.88 mg), mannitol (16.8 mg), polysorbate 80 (0.16 mg) and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
adalimumab,"HYRIMOZ (ADALIMUMAB-ADAZ) INJECTION, SOLUTION HYRIMOZ (ADALIMUMAB-ADAZ) KIT [SANDOZ INC]",1ac7d061-3380-468c-b077-c05f8dfbc829,"Aug 19, 2026",subcutaneous,5.2,False,citrate,1.23,polysorbate 80,0.1,,148.0,0.8,5.0,"Each 0.8 mL of HYRIMOZ contains adalimumab-adaz (40 mg), adipic acid (2.69 mg), citric acid monohydrate (0.206 mg), mannitol (9.6 mg), polysorbate 80 (0.8 mg), sodium chloride (4.93 mg), and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
adalimumab,"HYRIMOZ (ADALIMUMAB-ADAZ) INJECTION, SOLUTION HYRIMOZ (ADALIMUMAB-ADAZ) KIT [SANDOZ INC]",1ac7d061-3380-468c-b077-c05f8dfbc829,"Aug 19, 2026",subcutaneous,5.2,False,citrate,1.23,polysorbate 80,0.1,,148.0,0.4,5.0,"Each 0.4 mL of HYRIMOZ contains adalimumab-adaz (20 mg), adipic acid (1.34 mg), citric acid monohydrate (0.103 mg), mannitol (4.8 mg), polysorbate 80 (0.4 mg), sodium chloride (2.46 mg), and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
adalimumab,"HYRIMOZ (ADALIMUMAB-ADAZ) INJECTION, SOLUTION HYRIMOZ (ADALIMUMAB-ADAZ) KIT [SANDOZ INC]",1ac7d061-3380-468c-b077-c05f8dfbc829,"Aug 19, 2026",subcutaneous,5.2,False,,,polysorbate 80,0.04,,148.0,0.2,3.0,"Each 0.2 mL of HYRIMOZ contains adalimumab-adaz (20 mg), adipic acid (0.44 mg), mannitol (8.4 mg), polysorbate 80 (0.08 mg) and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
adalimumab,"HYRIMOZ (ADALIMUMAB-ADAZ) INJECTION, SOLUTION HYRIMOZ (ADALIMUMAB-ADAZ) KIT [SANDOZ INC]",1ac7d061-3380-468c-b077-c05f8dfbc829,"Aug 19, 2026",subcutaneous,5.2,False,,,polysorbate 80,0.04,,148.0,0.1,3.0,"Each 0.1 mL of HYRIMOZ contains adalimumab-adaz (10 mg), adipic acid (0.22 mg), mannitol (4.2 mg), polysorbate 80 (0.04 mg) and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
adalimumab,ADALIMUMAB (ADALIMUMAB-FKJP) KIT [BIOCON BIOLOGICS INC],5cde907d-6747-0e62-db25-1718ee717fe7,"Jul 22, 2026",subcutaneous,5.2,False,glutamate,12.74,polysorbate 80,0.1,,148.0,0.8,4.0,"Each 0.8 mL of Adalimumab-fkjp contains adalimumab-fkjp (40 mg), methionine (0.60 mg), monosodium glutamate (1.50 mg), polysorbate 80 (0.80 mg), sorbitol (38.2 mg) and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
adalimumab,ADALIMUMAB (ADALIMUMAB-FKJP) KIT [BIOCON BIOLOGICS INC],5cde907d-6747-0e62-db25-1718ee717fe7,"Jul 22, 2026",subcutaneous,5.2,False,glutamate,12.74,polysorbate 80,0.1,,148.0,0.4,4.0,"Each 0.4 mL of Adalimumab-fkjp contains adalimumab-fkjp (20 mg), methionine (0.30 mg), monosodium glutamate (0.75 mg), polysorbate 80 (0.40 mg), sorbitol (19.1 mg) and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
adalimumab,"SIMLANDI (ADALIMUMAB-RYVK) KIT [TEVA PHARMACEUTICALS USA, INC.]",12f609c9-2088-bb05-e063-6394a90a9ecc,"Jul 22, 2026",subcutaneous,5.3,True,,,polysorbate 80,0.1,,148.0,0.8,3.0,"Each 0.8 mL of SIMLANDI contains adalimumab-ryvk (80 mg), polysorbate 80 (0.80 mg), sodium chloride (0.47 mg), sucrose (69.83 mg), and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
adalimumab,"SIMLANDI (ADALIMUMAB-RYVK) KIT [TEVA PHARMACEUTICALS USA, INC.]",12f609c9-2088-bb05-e063-6394a90a9ecc,"Jul 22, 2026",subcutaneous,5.3,True,,,polysorbate 80,0.1,,148.0,0.4,3.0,"Each 0.4 mL of SIMLANDI contains adalimumab-ryvk (40 mg), polysorbate 80 (0.40 mg), sodium chloride (0.23 mg), sucrose (34.9 mg), and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
adalimumab,"SIMLANDI (ADALIMUMAB-RYVK) KIT [TEVA PHARMACEUTICALS USA, INC.]",12f609c9-2088-bb05-e063-6394a90a9ecc,"Jul 22, 2026",subcutaneous,5.3,True,,,polysorbate 80,0.1,,148.0,0.2,3.0,"Each 0.2 mL of SIMLANDI contains adalimumab-ryvk (20 mg), polysorbate 80 (0.20 mg), sodium chloride (0.12 mg), sucrose (17.46 mg), and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
adalimumab,ABRILADA (ADALIMUMAB-AFZB) KIT [A-S MEDICATION SOLUTIONS],1602cfaf-9ddd-4eb6-b847-10a4eebcf5e5,"Aug 17, 2026",subcutaneous,5.5,False,histidine,20.04,polysorbate 80,0.02,,148.0,0.8,6.0,"Each 0.8 mL of ABRILADA contains adalimumab-afzb (40 mg), edetate disodium dihydrate (0.04 mg), L-histidine (0.63mg), L-histidine hydrochloride monohydrate (2.51 mg), L-methionine (0.16 mg), polysorbate 80 (0.16 mg), sucrose (68 mg), and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
adalimumab,ABRILADA (ADALIMUMAB-AFZB) KIT [A-S MEDICATION SOLUTIONS],1602cfaf-9ddd-4eb6-b847-10a4eebcf5e5,"Aug 17, 2026",subcutaneous,5.5,False,histidine,20.0,polysorbate 80,0.02,,148.0,0.4,6.0,"Each 0.4 mL of ABRILADA contains adalimumab-afzb (20 mg), edetate disodium dihydrate (0.02 mg), L-histidine (0.314 mg), L-histidine hydrochloride monohydrate (1.253 mg), L-methionine (0.08 mg), polysorbate 80 (0.08 mg), sucrose (34 mg), and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
adalimumab,ABRILADA (ADALIMUMAB-AFZB) KIT [A-S MEDICATION SOLUTIONS],1602cfaf-9ddd-4eb6-b847-10a4eebcf5e5,"Aug 17, 2026",subcutaneous,5.5,False,histidine,19.99,polysorbate 80,0.02,,148.0,0.2,6.0,"Each 0.2 mL of ABRILADA contains adalimumab-afzb (10 mg), edetate disodium dihydrate (0.01 mg), L-histidine (0.157 mg), L-histidine hydrochloride monohydrate (0.626 mg), L-methionine (0.04 mg), polysorbate 80 (0.04 mg), sucrose (17 mg), and Water for Injection, USP.",8.341773796081544,24.8864944,-0.2868421052631579,0.1096491228070175,44.6890350877193,5.56751324913689,3.680818423269959,2.338901651169347,0.3903508771929824,G1,Kappa,TNF/TNFA,Whole mAb
alemtuzumab,CAMPATH (ALEMTUZUMAB) INJECTION [GENZYME CORPORATION],4f5f7255-7abc-4328-bd1a-ceaf139ef3e0,"Nov 19, 2025",intravenous,7.1,True,,,,,,,,0.0,"Each single-dose vial of CAMPATH contains 30 mg alemtuzumab, 8.0 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.",9.142664527893068,25.190023000000007,-0.3859649122807019,0.1096491228070175,40.19872807017543,9.382129029849688,7.660696053893833,6.338759473868904,0.3508771929824561,G1,Kappa,CD52,Whole mAb
alemtuzumab,"LEMTRADA (ALEMTUZUMAB) INJECTION, SOLUTION, CONCENTRATE [GENZYME CORPORATION]",6236b0bc-82e9-4447-9a78-f57d94770269,"Nov 19, 2025",intravenous,7.2,False,,,polysorbate 80,0.01,,,1.0,5.0,"Each 1 mL of solution contains 10 mg alemtuzumab, dibasic sodium phosphate (1.15 mg), disodium edetate dihydrate (0.0187 mg), polysorbate 80 (0.1 mg), potassium chloride (0.2 mg), potassium dihydrogen phosphate (0.2 mg), sodium chloride (8 mg), and Water for Injection, USP.",9.142664527893068,25.190023000000007,-0.3859649122807019,0.1096491228070175,40.19872807017543,9.382129029849688,7.660696053893833,6.338759473868904,0.3508771929824561,G1,Kappa,CD52,Whole mAb
alirocumab,"PRALUENT (ALIROCUMAB) INJECTION, SOLUTION [SANOFI-AVENTIS U.S. LLC]",446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4,"Jul 24, 2026",subcutaneous,6.0,False,,,,,75.0,146.0,,0.0,"Each 75 mg/mL pre-filled pen contains 75 mg alirocumab, histidine (8 mM), polysorbate 20 (0.1 mg), sucrose (100 mg), and Water for Injection USP, to pH 6.0.",7.862838172912598,25.2828045,-0.3558441558441559,0.1168831168831169,34.99264069264069,3.5981746540106334,1.921151239364062,1.0994454378631362,0.3679653679653679,G1,Kappa,PCSK9,Whole mAb
alirocumab,"PRALUENT (ALIROCUMAB) INJECTION, SOLUTION [SANOFI-AVENTIS U.S. LLC]",446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4,"Jul 24, 2026",subcutaneous,6.0,False,,,,,150.0,146.0,,0.0,"Each 150 mg/mL pre-filled pen contains 150 mg alirocumab, histidine (6 mM), polysorbate 20 (0.1 mg), sucrose (100 mg), and Water for Injection USP, to pH 6.0.",7.862838172912598,25.2828045,-0.3558441558441559,0.1168831168831169,34.99264069264069,3.5981746540106334,1.921151239364062,1.0994454378631362,0.3679653679653679,G1,Kappa,PCSK9,Whole mAb
alirocumab,"PRALUENT (ALIROCUMAB) INJECTION, SOLUTION [REGENERON PHARMACEUTICALS, INC.]",7bcfbac2-e8ac-4569-8edc-bcde3b1fd172,"Jul 24, 2026",subcutaneous,6.0,False,,,,,75.0,146.0,,0.0,"Each 75 mg/mL pre-filled pen contains 75 mg alirocumab, histidine (8 mM), polysorbate 20 (0.1 mg), sucrose (100 mg), and Water for Injection USP, to pH 6.0.",7.862838172912598,25.2828045,-0.3558441558441559,0.1168831168831169,34.99264069264069,3.5981746540106334,1.921151239364062,1.0994454378631362,0.3679653679653679,G1,Kappa,PCSK9,Whole mAb
alirocumab,"PRALUENT (ALIROCUMAB) INJECTION, SOLUTION [REGENERON PHARMACEUTICALS, INC.]",7bcfbac2-e8ac-4569-8edc-bcde3b1fd172,"Jul 24, 2026",subcutaneous,6.0,False,,,,,150.0,146.0,,0.0,"Each 150 mg/mL pre-filled pen contains 150 mg alirocumab, histidine (6 mM), polysorbate 20 (0.1 mg), sucrose (100 mg), and Water for Injection USP, to pH 6.0.",7.862838172912598,25.2828045,-0.3558441558441559,0.1168831168831169,34.99264069264069,3.5981746540106334,1.921151239364062,1.0994454378631362,0.3679653679653679,G1,Kappa,PCSK9,Whole mAb
ansuvimab,"EBANGA (ANSUVIMAB) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [EMERGENT BIODEFENSE OPERATIONS LANSING LLC]",de220c8f-ffcb-4522-a6a2-c7d6ce5de1b5,"Aug 17, 2026",,6.0,False,,,,,,147.0,,0.0,"Each single-dose vial delivers 400 mg of ansuvimab-zykl, and L-histidine (12.4 mg), L-histidine HCl (16.8 mg), polysorbate 80 (1.6 mg), and sucrose (657 mg).",8.392897224426271,24.1378265,-0.1203539823008848,0.0884955752212389,43.42123893805309,6.425085350313999,4.428545595916213,2.5820243351052463,0.3938053097345133,G1,Kappa,Zaire Ebolavirus Glycoprotein,Whole mAb
ansuvimab,"EBANGA (ANSUVIMAB) KIT [RIDGEBACK BIOTHERAPEUTICS, LP]",9c008384-379d-48d3-b5a5-9809ed0f655c,"Feb 12, 2025",,6.0,False,,,,,,147.0,,0.0,"Each single-dose vial delivers 400 mg of ansuvimab-zykl, and L-histidine (12.4 mg), L-histidine HCl (16.8 mg), polysorbate 80 (1.6 mg), and sucrose (657 mg).",8.392897224426271,24.1378265,-0.1203539823008848,0.0884955752212389,43.42123893805309,6.425085350313999,4.428545595916213,2.5820243351052463,0.3938053097345133,G1,Kappa,Zaire Ebolavirus Glycoprotein,Whole mAb
atezolizumab,"TECENTRIQ (ATEZOLIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.]",6fa682c9-a312-4932-9831-f286908660ee,"May 28, 2026",intravenous,5.8,False,histidine,19.98,polysorbate 20,0.04,,,20.0,3.0,"Each 20 mL vial contains 1200 mg of atezolizumab and is formulated in glacial acetic acid (16.5 mg), L-histidine (62 mg), polysorbate 20 (8 mg), and sucrose (821.6 mg), with a pH of 5.8.",7.874184608459473,24.4799899,-0.232,0.1333333333333333,40.501333333333335,5.351456588077808,3.4202528794961387,1.5771131710348465,0.3911111111111111,G1,Kappa,PDL1/CD274,Whole mAb
atezolizumab,"TECENTRIQ (ATEZOLIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.]",6fa682c9-a312-4932-9831-f286908660ee,"May 28, 2026",intravenous,5.8,False,histidine,19.98,polysorbate 20,0.04,,,14.0,3.0,"Each 14 mL vial contains 840 mg of atezolizumab and is formulated in glacial acetic acid (11.5 mg), L-histidine (43.4 mg), polysorbate 20 (5.6 mg), and sucrose (575.1 mg) with a pH of 5.8.",7.874184608459473,24.4799899,-0.232,0.1333333333333333,40.501333333333335,5.351456588077808,3.4202528794961387,1.5771131710348465,0.3911111111111111,G1,Kappa,PDL1/CD274,Whole mAb
atezolizumab,"TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) INJECTION [GENENTECH, INC.]",a617b089-ce66-464b-987b-b45d029b4d6f,"May 28, 2026",subcutaneous,5.8,False,,,polysorbate 20,0.06,,61.0,15.0,2.0,"Each 15 mL single-dose vial contains 1,875 mg of atezolizumab, 30,000 units of hyaluronidase, histidine (46.5 mg), methionine (22.4 mg), polysorbate 20 (9 mg), sucrose (1,232 mg), and water for injection, adjusted to pH 5.8 with acetic acid.",7.874184608459473,24.4799899,-0.232,0.1333333333333333,40.501333333333335,5.351456588077808,3.4202528794961387,1.5771131710348465,0.3911111111111111,G1,Kappa,PDL1/CD274,Whole mAb
bedinvetmab,"LIBRELA (BEDINVETMAB INJECTION) INJECTION, SOLUTION [ZOETIS INC.]",61c7b4e0-aab6-4cf5-8471-f94be438c758,"Feb 24, 2025",,5.0,False,,,,,30.0,,,0.0,"DESCRIPTION LIBRELA (bedinvetmab injection) is a sterile injectable solution containing 5, 10, 15, 20, or 30 mg/mL of bedinvetmab in 20 mM histidine buffer pH 5.0 [(0.027% w/v L- histidine and 0.382% w/v histidine HCl monohydrate), 8.5% w/v trehalose dihydrate, 0.005% w/v disodium EDTA dihydrate, 0.01% w/v L-methionine, and 0.1% w/v poloxamer 188].",5.9283296585083,24.9384823,-0.1412765957446808,0.0978723404255319,37.53234042553192,3.4755864433005383,0.9603940228628368,-1.936993224386847,0.3702127659574468,G2,Lambda,NGFB (Canine),Canine Whole mAb
belimumab,"BENLYSTA (BELIMUMAB) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION BENLYSTA (BELIMUMAB) SOLUTION [GLAXOSMITHKLINE LLC]",2fa3c528-1777-4628-8a55-a69dae2381a3,"Sep 02, 2026",subcutaneous,6.0,False,histidine,11.92,polysorbate 80,0.01,,147.0,1.0,4.0,"Each 1 mL delivers 200 mg belimumab, L-arginine hydrochloride (5.3 mg), L-histidine (0.65 mg), L-histidine monohydrochloride (1.2 mg), polysorbate 80 (0.1 mg), and sodium chloride (6.7 mg), with a pH of 6.0.",7.001961326599121,24.679043599999986,-0.3623376623376624,0.0865800865800865,41.264069264069256,4.613359132303881,2.450098282659621,0.5843674312873349,0.354978354978355,G1,Lambda,TNFSF13B/CD257/BAFF,Whole mAb
belimumab,"BENLYSTA (BELIMUMAB) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION BENLYSTA (BELIMUMAB) SOLUTION [GLAXOSMITHKLINE LLC]",2fa3c528-1777-4628-8a55-a69dae2381a3,"Sep 02, 2026",subcutaneous,6.5,False,,,,,,147.0,,0.0,"Each mL delivers 80 mg belimumab, citric acid (0.16 mg), polysorbate 80 (0.4 mg), sodium citrate (2.7 mg), and sucrose (80 mg), with a pH of 6.5.",7.001961326599121,24.679043599999986,-0.3623376623376624,0.0865800865800865,41.264069264069256,4.613359132303881,2.450098282659621,0.5843674312873349,0.354978354978355,G1,Lambda,TNFSF13B/CD257/BAFF,Whole mAb
benralizumab,"FASENRA (BENRALIZUMAB) INJECTION, SOLUTION [ASTRAZENECA PHARMACEUTICALS LP]",da6aca1a-19ed-44a4-abb7-696c7d58b784,"May 28, 2026",subcutaneous,6.0,True,histidine,11.45,polysorbate 20,0.006,,150.0,0.5,3.0,"Each 10 mg single-dose prefilled syringe delivers 0.5 mL containing 10 mg benralizumab, L-histidine (0.7 mg); L-histidine hydrochloride monohydrate (1.2 mg); polysorbate 20 (0.03 mg); α,α‑trehalose dihydrate (47 mg); and Water for Injection, USP, at pH of 5.5 – 6.5.",8.766813850402833,25.190954600000005,-0.3947368421052633,0.1184210526315789,34.503947368421045,7.643939570483047,5.689621484267357,4.336820315019084,0.3552631578947368,G1,Kappa,IL5RA/CD125,Whole mAb
benralizumab,"FASENRA (BENRALIZUMAB) INJECTION, SOLUTION [ASTRAZENECA PHARMACEUTICALS LP]",da6aca1a-19ed-44a4-abb7-696c7d58b784,"May 28, 2026",subcutaneous,6.0,True,histidine,10.97,polysorbate 20,0.006,,150.0,1.0,3.0,"Each 30 mg single-dose prefilled syringe or single-dose autoinjector delivers 1 mL containing 30 mg benralizumab, L-histidine (1.4 mg); L-histidine hydrochloride monohydrate (2.3 mg); polysorbate 20 (0.06 mg); α,α‑trehalose dihydrate (95 mg); and Water for Injection, USP, at pH of 5.5 – 6.5.",8.766813850402833,25.190954600000005,-0.3947368421052633,0.1184210526315789,34.503947368421045,7.643939570483047,5.689621484267357,4.336820315019084,0.3552631578947368,G1,Kappa,IL5RA/CD125,Whole mAb
bimekizumab,"BIMZELX (BIMEKIZUMAB) INJECTION, SOLUTION [UCB, INC.]",26b88358-871f-4c80-9d80-b2fb16477f81,"Jun 18, 2025",subcutaneous,5.1,False,acetate,34.5,polysorbate 80,0.04,160.0,150.0,1.0,3.0,"Each BIMZELX 1 mL (160 mg/mL) prefilled syringe or prefilled autoinjector delivers 1 mL containing 160 mg bimekizumab-bkzx, glacial acetic acid (1.23 mg), glycine (16.5 mg), polysorbate 80 (0.4 mg), sodium acetate (2.83 mg), and Water for Injection, USP at pH 5.1.",7.867028617858888,25.7885442,-0.3543103448275863,0.1249999999999999,35.21853448275862,4.829372970730891,2.710235628955288,1.3418768186575836,0.3836206896551724,G1,Kappa,IL17A,Whole mAb
bimekizumab,"BIMZELX (BIMEKIZUMAB) INJECTION, SOLUTION [UCB, INC.]",26b88358-871f-4c80-9d80-b2fb16477f81,"Jun 18, 2025",subcutaneous,5.1,False,acetate,34.44,polysorbate 80,0.04,160.0,150.0,2.0,3.0,"Each BIMZELX 2 mL (160 mg/mL) prefilled syringe or prefilled autoinjector delivers 2 mL containing 320 mg bimekizumab-bkzx, glacial acetic acid (2.46 mg), glycine (33.0 mg), polysorbate 80 (0.8 mg), sodium acetate (5.65 mg), and Water for Injection, USP at pH 5.1.",7.867028617858888,25.7885442,-0.3543103448275863,0.1249999999999999,35.21853448275862,4.829372970730891,2.710235628955288,1.3418768186575836,0.3836206896551724,G1,Kappa,IL17A,Whole mAb
brolucizumab,"BEOVU (BROLUCIZUMAB) INJECTION, SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]",5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d,"Nov 17, 2025",,7.2,False,citrate,10.0,,,,,0.05,2.0,"Each single-dose pre-filled syringe and vial is designed to deliver 0.05 mL of solution containing 6 mg brolucizumab-dbll, polysorbate 80 (0.02%), sodium citrate (10 mM), sucrose (5.8%), and Water for Injection, USP and with a pH of approximately 7.2.",4.93211269378662,24.867517100000004,-0.1156521739130433,0.117391304347826,31.50652173913044,-1.3588895085217247,-3.3112040365462407,-4.659336677731651,0.4043478260869565,na,Kappa,VEGFA,scFv
burosumab,"CRYSVITA (BUROSUMAB) INJECTION [KYOWA KIRIN, INC.]",102f96a0-6e3a-4fc1-b204-34d604683af6,"Jul 03, 2026",subcutaneous,6.25,False,,,polysorbate 80,0.05,,,1.0,3.0,"Each 1 mL of solution contains 10 mg, 20 mg or 30 mg of burosumab-twza, L-histidine (1.55 mg), L-methionine (1.49 mg), polysorbate 80 (0.5 mg), D-sorbitol (45.91 mg) in Water for Injection, USP.",7.803656196594239,24.20783519999999,-0.232286995515695,0.1076233183856502,37.08475336322869,4.455726208945524,2.6686729616222995,1.340514820432584,0.3721973094170404,G1,Kappa,FGF23,Whole mAb
caplacizumab,CABLIVI (CAPLACIZUMAB) KIT [GENZYME CORPORATION],2348f06e-8004-4040-832e-e9e86a39f905,"Apr 28, 2026",,6.5,False,,,,,,28.0,,0.0,"Each single-dose vial delivers 11 mg caplacizumab-yhdp, anhydrous citric acid (0.18 mg), polysorbate 80 (0.10 mg), sucrose (62 mg), and trisodium citrate dihydrate (4.91 mg).",9.070137596130367,14.027489199999986,-0.3569230769230769,0.1,39.5876923076923,4.114404583851413,3.1131154790734907,2.920653149754871,0.3846153846153846,na,na,VWF,Nanobody
cemiplimab,"LIBTAYO (CEMIPLIMAB-RWLC) INJECTION [REGENERON PHARMACEUTICALS, INC.]",4347ae1f-d397-4f18-8b70-03897e1c054a,"May 20, 2026",intravenous,6.0,False,,,,,,146.0,,0.0,"Each mL contains cemiplimab-rwlc 50 mg, L-histidine (0.74 mg), L-histidine monohydrochloride monohydrate (1.1 mg), sucrose (50 mg), L-proline (15 mg), polysorbate 80 (2 mg), and Water for Injection, USP.",7.88198528289795,24.230786700000003,-0.1647321428571428,0.125,32.75089285714286,3.300981036130815,1.888659845684124,1.098682937136446,0.3705357142857143,G4,Kappa,PDCD1/CD279/PD1,Whole mAb
certolizumab,"CIMZIA (CERTOLIZUMAB PEGOL) KIT CIMZIA (CERTOLIZUMAB PEGOL) INJECTION, SOLUTION [UCB, INC.]",b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,"Feb 26, 2026",subcutaneous,5.2,False,,,,,,,,0.0,"Each single-dose vial provides 200 mg certolizumab pegol, lactic acid (0.9 mg), polysorbate (0.1 mg), and sucrose (100 mg).",7.826735877990724,24.6203115,-0.2275555555555555,0.1377777777777777,32.201777777777764,2.481611765688589,1.1452309124457054,0.8534875026625274,0.4044444444444444,G1,Kappa,TNF/TNFA,Fab
certolizumab,"CIMZIA (CERTOLIZUMAB PEGOL) KIT CIMZIA (CERTOLIZUMAB PEGOL) INJECTION, SOLUTION [UCB, INC.]",b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,"Feb 26, 2026",subcutaneous,5.2,False,,,,,,,1.0,1.0,"Each prefilled syringe delivers 1 mL of solution containing 200 mg certolizumab pegol, sodium acetate (1.36 mg), sodium chloride (7.31 mg), and Water for Injection, USP.",7.826735877990724,24.6203115,-0.2275555555555555,0.1377777777777777,32.201777777777764,2.481611765688589,1.1452309124457054,0.8534875026625274,0.4044444444444444,G1,Kappa,TNF/TNFA,Fab
cetuximab,ERBITUX (CETUXIMAB) SOLUTION [IMCLONE LLC],8bc6397e-4bd8-4d37-a007-a327e4da34d9,"Apr 30, 2026",intravenous,7.2,True,phosphate,9.98,,,,152.0,1.0,2.0,"Each 1 mL of solution contains 2 mg of cetuximab, sodium chloride (8.48 mg), sodium phosphate dibasic heptahydrate (1.88 mg), sodium phosphate monobasic monohydrate (0.41 mg), and Water for Injection, USP at pH of 7.0 to 7.4.",7.80359172821045,24.885370100000003,-0.3172566371681417,0.1194690265486725,45.571681415929206,4.346766593713778,2.6573364896584306,1.33812060246182,0.3584070796460177,G1,Kappa,EGFR/ERBB1/HER1,Whole mAb
cosibelimab,"UNLOXCYT (COSIBELIMAB) INJECTION, SOLUTION [SUN PHARMACEUTICAL INDUSTRIES, INC.]",06bdadd5-d2db-406f-a3f8-de47f48a52e3,"Dec 09, 2025",intravenous,5.3,False,,,,,,147.0,,0.0,"Each mL of solution contains 60 mg of cosibelimab-ipdl, acetic acid (0.24 mg), mannitol (37.35 mg), polysorbate 80 (1.1 mg), sodium acetate (1.31 mg), sodium chloride (4.09 mg), and Water for Injection, USP.",5.739453697204591,24.971316100000003,-0.3655172413793104,0.0948275862068965,47.18491379310344,1.9412205766315664,-0.2770132972773365,-1.6536847231830638,0.3448275862068966,G1,Lambda,PDL1/CD274,Whole mAb
crizanlizumab,ADAKVEO (CRIZANLIZUMAB) INJECTION [NOVARTIS PHARMACEUTICALS CORPORATION],b2b7f8b4-fe9a-4a86-8129-9e43f99a20c6,"Jun 08, 2026",intravenous,6.0,False,citrate,19.57,polysorbate 80,0.02,,146.0,10.0,3.0,"Each 10 mL vial contains 100 mg crizanlizumab-tmca, citric acid (5.4 mg), polysorbate 80 (2 mg), sodium citrate (50.5 mg), sucrose (753.3 mg), and water for injection with a pH of 6.",5.529035758972167,25.5231071,-0.4901287553648071,0.1158798283261802,37.04077253218884,1.1925780479568326,-1.0137044073152195,-1.8974154902295053,0.3562231759656652,G2,Kappa,SELP/CD62,Whole mAb
datopotamab,"DATROWAY (DATOPOTAMAB DERUXTECAN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [DAIICHI SANKYO INC.]",2950227c-6230-4ca4-a135-46e44d9424a0,"Jun 03, 2026",intravenous,6.0,False,,,,,,,,0.0,"Each vial delivers 100 mg of datopotamab deruxtecan-dlnk, L-histidine (3.88 mg), L-histidine hydrochloride monohydrate (5.25 mg), polysorbate 80 (1.50 mg), and sucrose (450 mg).",8.78202838897705,24.7484399,-0.2478070175438596,0.1228070175438596,31.866666666666656,7.308514632406876,5.652546974277152,4.335283565685805,0.3815789473684211,G1,Kappa,TACSTD2/TROP2/EGP1,Whole mAb
denosumab,"BILPREVDA (DENOSUMAB) INJECTION, SOLUTION [ORGANON LLC]",b1f0590e-f5bb-44ac-99a0-4aa4596c7e54,"Aug 20, 2026",subcutaneous,5.2,False,,,,,,147.0,,0.0,"Each single-dose vial contains 120 mg denosumab-nxxp, glacial acetic acid (1.84 mg), polysorbate 20 (0.17 mg), sorbitol (78.2 mg), Water for Injection (USP), and sodium hydroxide to a pH of 5.2.",8.891044425964356,24.745412999999985,-0.2643478260869565,0.108695652173913,41.48569565217391,5.631714331706721,4.1628014847005455,3.86106232915702,0.3608695652173913,G2,Kappa,TNFSF11/CD254/RANKL/TRANCE/OPGL/ODF,Whole mAb
denosumab,"BILDYOS (DENOSUMAB) INJECTION, SOLUTION [ORGANON LLC]",b9e32bf7-d70a-4083-8577-c15751c7f769,"Aug 20, 2026",subcutaneous,5.2,False,acetate,16.99,polysorbate 20,0.01,60.0,147.0,1.0,3.0,"Each 1 mL single-dose prefilled syringe of Bildyos contains 60 mg denosumab-nxxp (60 mg/mL solution), glacial acetic acid (1.02 mg), polysorbate 20 (0.1 mg), sorbitol (47.0 mg), Water for Injection (USP), and sodium hydroxide to a pH of 5.2.",8.891044425964356,24.745412999999985,-0.2643478260869565,0.108695652173913,41.48569565217391,5.631714331706721,4.1628014847005455,3.86106232915702,0.3608695652173913,G2,Kappa,TNFSF11/CD254/RANKL/TRANCE/OPGL/ODF,Whole mAb
denosumab,BOSAYA (DENOSUMAB-KYQQ) INJECTION [BIOCON BIOLOGICS INC.],1e5e8c88-3c65-3076-e44b-02d92c2d343d,"Jul 30, 2026",subcutaneous,5.2,False,acetate,13.1,polysorbate 20,0.01,,147.0,1.0,3.0,"Each 1 mL single-dose prefilled syringe of Bosaya contains 60 mg denosumab-kyqq, glacial acetic acid (0.234 mg),polysorbate 20 (0.1 mg), sodium acetate (1.075 mg), sorbitol (47 mg), Water for Injection (USP), and may contain sodium hydroxide/acetic acid to adjust pH of 5.2.",8.891044425964356,24.745412999999985,-0.2643478260869565,0.108695652173913,41.48569565217391,5.631714331706721,4.1628014847005455,3.86106232915702,0.3608695652173913,G2,Kappa,TNFSF11/CD254/RANKL/TRANCE/OPGL/ODF,Whole mAb
donanemab,"KISUNLA (DONANEMAB-AZBT) INJECTION, SOLUTION [ELI LILLY AND COMPANY]",190352d4-ef62-4679-b4fa-e846e2766afa,"Jan 02, 2026",intravenous,6.0,True,,,,,,145.0,,0.0,"Each mL of solution contains 17.5 mg donanemab-azbt, anhydrous citric acid (0.32 mg), polysorbate 80 (0.20 mg), sodium citrate (2.15 mg), sucrose (80 mg), and Water for Injection, USP, at a pH of 5.5 to 6.5.",8.771584510803223,24.8466724,-0.3348017621145375,0.1101321585903083,34.57709251101321,6.712841937297256,4.934633823660559,4.099101375861334,0.3612334801762114,G1,Kappa,APP,Whole mAb
dostarlimab,JEMPERLI (DOSTARLIMAB) INJECTION [GLAXOSMITHKLINE LLC],095eab9f-545a-4f12-bfb7-19477fb901a5,"Mar 30, 2026",,6.0,False,,,,,,,,0.0,"Each mL of solution contains 50 mg of dostarlimab-gxly, citric acid monohydrate (0.48 mg), L-arginine hydrochloride (21.07 mg), polysorbate 80 (0.2 mg), sodium chloride (1.81 mg), trisodium citrate dihydrate (6.68 mg), and Water for Injection, USP.",6.969619941711425,24.4108931,-0.288340807174888,0.1390134529147982,41.86143497757848,3.420312880467184,1.6648045084836882,0.3347905094124405,0.3811659192825112,G4,Kappa,PDCD1/CD279/PD1,Whole mAb
dupilumab,"DUPIXENT (DUPILUMAB) INJECTION, SOLUTION [SANOFI-AVENTIS U.S. LLC]",595f437d-2729-40bb-9c62-c8ece1f82780,"Aug 07, 2026",subcutaneous,5.9,False,histidine+acetate,32.17,polysorbate 80,0.2,,147.0,2.0,5.0,"Each 300 mg pre-filled syringe or pre-filled pen delivers 300 mg dupilumab in 2 mL which also contains L-arginine hydrochloride (10.5 mg), L-histidine (6.2 mg), polysorbate 80 (4 mg), sodium acetate (2 mg), sucrose (100 mg), and water for injection, pH 5.9.",7.840661048889161,25.89570719999999,-0.2940928270042194,0.1139240506329114,43.29413502109704,2.852435730695276,1.1860308712264578,0.8593196316639756,0.3713080168776371,G4,Kappa,IL4R/CD124,Whole mAb
dupilumab,"DUPIXENT (DUPILUMAB) INJECTION, SOLUTION [SANOFI-AVENTIS U.S. LLC]",595f437d-2729-40bb-9c62-c8ece1f82780,"Aug 07, 2026",subcutaneous,5.9,False,histidine+acetate,32.62,polysorbate 80,0.20175,,147.0,1.14,5.0,"Each 200 mg pre-filled syringe or pre-filled pen delivers 200 mg dupilumab in 1.14 mL which also contains L-arginine hydrochloride (12 mg), L-histidine (3.5 mg), polysorbate 80 (2.3 mg), sodium acetate (1.2 mg), sucrose (57 mg), and water for injection, pH 5.9.",7.840661048889161,25.89570719999999,-0.2940928270042194,0.1139240506329114,43.29413502109704,2.852435730695276,1.1860308712264578,0.8593196316639756,0.3713080168776371,G4,Kappa,IL4R/CD124,Whole mAb
eculizumab,"BKEMV (ECULIZUMAB-AEEB) INJECTION, SOLUTION, CONCENTRATE [AMGEN INC]",002f9748-b0e8-4b6e-a38b-56930a839491,"Jul 13, 2026",intravenous,5.2,False,acetate,9.99,polysorbate 80,0.01,,148.0,30.0,2.0,"The product is formulated at pH 5.2 and each 30 mL vial contains 300 mg of eculizumab-aeeb, sorbitol (E420) (1500 mg), acetic acid (18 mg), polysorbate 80 (3 mg) (vegetable origin), edetate disodium (EDTA) (0.6 mg), sodium hydroxide may be added to adjust pH, and Water for Injection, USP.",5.2288122177124015,25.0396742,-0.2755458515283843,0.1222707423580786,31.77903930131004,-0.1829027621487036,-1.8170892816720388,-2.1389272828492647,0.3755458515283842,G2,Kappa,C5,Whole mAb
eculizumab,"SOLIRIS (ECULIZUMAB) INJECTION, SOLUTION, CONCENTRATE [ALEXION PHARMACEUTICALS INC.]",ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,"Jul 13, 2026",intravenous,7.0,False,phosphate,16.37,,,,148.0,30.0,3.0,"The product is formulated at pH 7 and each 30 mL vial contains 300 mg of eculizumab, polysorbate 80 (6.6 mg) (vegetable origin), sodium chloride (263.1 mg), sodium phosphate dibasic (53.4 mg), sodium phosphate monobasic (13.8 mg), and Water for Injection, USP.",5.2288122177124015,25.0396742,-0.2755458515283843,0.1222707423580786,31.77903930131004,-0.1829027621487036,-1.8170892816720388,-2.1389272828492647,0.3755458515283842,G2,Kappa,C5,Whole mAb
emicizumab,"HEMLIBRA (EMICIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.]",2483adba-fab6-4d1b-96c5-c195577ed071,"Jul 21, 2025",subcutaneous,6.0,False,,,,,,145.6,,0.0,"Each single-dose 12 mg vial contains a 0.4 mL solution of emicizumab-kxwh (12 mg), L-arginine (10.5 mg), L-histidine (1.2 mg), and poloxamer 188 (0.2 mg), adjusted to pH 6.0 with L-aspartic acid.",5.162537956237792,25.1075688,-0.6088495575221241,0.0973451327433628,45.5358407079646,-0.5101728452627601,-2.9806581598281765,-3.891107968614971,0.336283185840708,G4;G4,Kappa;Kappa,F9;F10,Bispecific mAb
emicizumab,"HEMLIBRA (EMICIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.]",2483adba-fab6-4d1b-96c5-c195577ed071,"Jul 21, 2025",subcutaneous,6.0,False,,,,,,145.6,,0.0,"Each single-dose 30 mg vial contains a 1 mL solution of emicizumab-kxwh (30 mg), L-arginine (26.1 mg), L-histidine (3.1 mg), and poloxamer 188 (0.5 mg), adjusted to pH 6.0 with L-aspartic acid.",5.162537956237792,25.1075688,-0.6088495575221241,0.0973451327433628,45.5358407079646,-0.5101728452627601,-2.9806581598281765,-3.891107968614971,0.336283185840708,G4;G4,Kappa;Kappa,F9;F10,Bispecific mAb
emicizumab,"HEMLIBRA (EMICIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.]",2483adba-fab6-4d1b-96c5-c195577ed071,"Jul 21, 2025",subcutaneous,6.0,False,,,,,,145.6,,0.0,"Each single-dose 60 mg vial contains a 0.4 mL solution of emicizumab-kxwh (60 mg), L-arginine (10.5 mg), L-histidine (1.2 mg), and poloxamer 188 (0.2 mg), adjusted to pH 6.0 with L-aspartic acid.",5.162537956237792,25.1075688,-0.6088495575221241,0.0973451327433628,45.5358407079646,-0.5101728452627601,-2.9806581598281765,-3.891107968614971,0.336283185840708,G4;G4,Kappa;Kappa,F9;F10,Bispecific mAb
emicizumab,"HEMLIBRA (EMICIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.]",2483adba-fab6-4d1b-96c5-c195577ed071,"Jul 21, 2025",subcutaneous,6.0,False,,,,,,145.6,,0.0,"Each single-dose 105 mg vial contains a 0.7 mL solution of emicizumab-kxwh (105 mg), L-arginine (18.3 mg), L-histidine (2.2 mg), and poloxamer 188 (0.4 mg), adjusted to pH 6.0 with L-aspartic acid.",5.162537956237792,25.1075688,-0.6088495575221241,0.0973451327433628,45.5358407079646,-0.5101728452627601,-2.9806581598281765,-3.891107968614971,0.336283185840708,G4;G4,Kappa;Kappa,F9;F10,Bispecific mAb
emicizumab,"HEMLIBRA (EMICIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.]",2483adba-fab6-4d1b-96c5-c195577ed071,"Jul 21, 2025",subcutaneous,6.0,False,,,,,,145.6,,0.0,"Each single-dose 150 mg vial contains a 1 mL solution of emicizumab-kxwh (150 mg), L-arginine (26.1 mg), L-histidine (3.1 mg), and poloxamer 188 (0.5 mg), adjusted to pH 6.0 with L-aspartic acid.",5.162537956237792,25.1075688,-0.6088495575221241,0.0973451327433628,45.5358407079646,-0.5101728452627601,-2.9806581598281765,-3.891107968614971,0.336283185840708,G4;G4,Kappa;Kappa,F9;F10,Bispecific mAb
emicizumab,"HEMLIBRA (EMICIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.]",2483adba-fab6-4d1b-96c5-c195577ed071,"Jul 21, 2025",subcutaneous,6.0,False,,,,,,145.6,,0.0,"Each single-dose 300 mg vial contains a 2 mL solution of emicizumab-kxwh (300 mg), L-arginine (52.3 mg), L-histidine (6.2 mg), and poloxamer 188 (1 mg), adjusted to pH 6.0 with L-aspartic acid.",5.162537956237792,25.1075688,-0.6088495575221241,0.0973451327433628,45.5358407079646,-0.5101728452627601,-2.9806581598281765,-3.891107968614971,0.336283185840708,G4;G4,Kappa;Kappa,F9;F10,Bispecific mAb
enfortumab,"PADCEV EJFV (ENFORTUMAB VEDOTIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [SEAGEN INC.]",b5631d3e-4604-4363-8f20-11dfc5a4a8ed,"Aug 17, 2026",intravenous,6.0,False,,,,,,,,0.0,"Each mL of reconstituted solution contains 10 mg of enfortumab vedotin-ejfv, histidine (1.4 mg), histidine hydrochloride monohydrate (2.31 mg), polysorbate 20 (0.2 mg), and trehalose dihydrate (55 mg) with a pH of 6.0.",8.346608924865723,24.118547999999983,-0.24375,0.1205357142857143,46.73437499999999,3.369837265274636,2.1332108422163367,1.8563539509787192,0.375,G1,Kappa,PVRL4/Nectin-4,Whole mAb ADC
eptinezumab,VYEPTI (EPTINEZUMAB-JJMR) INJECTION [LUNDBECK PHARMACEUTICALS LLC],79065861-6aa5-4d1f-829f-3a6471286b36,"Aug 20, 2026",intravenous,5.8,False,,,,,,,,0.0,"Each mL contains 100 mg eptinezumab-jjmr formulated in L-histidine (1 mg), L-histidine hydrochloride monohydrate (2.8 mg), polysorbate 80 (0.15 mg), sorbitol (40.5 mg), and Water for Injection, USP, at a pH of 5.8.",6.819280815124511,23.8464208,-0.1049327354260089,0.1076233183856502,38.09417040358743,2.412139167388012,0.8945341505757682,0.0360970243131612,0.3856502242152466,G1,Kappa,CALCA and CALCB,Whole mAb
erenumab,"AIMOVIG (ERENUMAB-AOOE) INJECTION AIMOVIG (ERENUMAB-AOOE) INJECTION, SOLUTION [AMGEN, INC]",b998ed05-94b0-47fd-b28f-cddd1e128fd8,"Jul 17, 2026",subcutaneous,5.2,False,,,polysorbate 80,0.01,,150.0,1.0,3.0,"Each 1 mL 70 mg single-dose prefilled autoinjector and 70 mg single-dose prefilled glass syringe contains 70 mg erenumab-aooe, acetate (1.5 mg), polysorbate 80 (0.10 mg), and sucrose (73 mg).",9.09850368499756,25.9016153,-0.264166666666667,0.1166666666666666,43.74583333333331,9.232054858424704,7.643409409858416,6.334022159716046,0.3708333333333333,G2,Lambda,CALCRL,Whole mAb
erenumab,"AIMOVIG (ERENUMAB-AOOE) INJECTION AIMOVIG (ERENUMAB-AOOE) INJECTION, SOLUTION [AMGEN, INC]",b998ed05-94b0-47fd-b28f-cddd1e128fd8,"Jul 17, 2026",subcutaneous,5.2,False,,,polysorbate 80,0.01,,150.0,1.0,3.0,"Each 1 mL 140 mg single-dose prefilled autoinjector and 140 mg single-dose prefilled glass syringe contains 140 mg erenumab-aooe, acetate (2.0 mg), polysorbate 80 (0.10 mg), and sucrose (65 mg).",9.09850368499756,25.9016153,-0.264166666666667,0.1166666666666666,43.74583333333331,9.232054858424704,7.643409409858416,6.334022159716046,0.3708333333333333,G2,Lambda,CALCRL,Whole mAb
evolocumab,"REPATHA (EVOLOCUMAB) INJECTION, SOLUTION REPATHA (EVOLOCUMAB) KIT [AMGEN USA INC.]",cd61e902-166d-4aa6-9f3c-a18c1008d07e,"Aug 21, 2026",subcutaneous,5.0,False,,,polysorbate 80,0.01,,,1.0,2.0,"Each 1 mL prefilled single-dose pen, prefilled single-dose SureClick® autoinjector and prefilled single-dose syringe contains 140 mg evolocumab, acetate (1.2 mg), polysorbate 80 (0.1 mg), proline (25 mg) in Water for Injection, USP.",7.853554725646973,23.752992000000003,-0.3683035714285713,0.0982142857142857,32.87683035714286,3.4156307976996265,1.9019672289327088,1.0965884763499243,0.34375,G2,Lambda,PCSK9,Whole mAb
faricimab,"VABYSMO (FARICIMAB) INJECTION, SOLUTION [GENENTECH, INC.]",04cc9ef7-c02a-4e92-a655-0062674e8487,"Apr 22, 2026",,5.5,False,,,polysorbate 20,0.04,,149.0,0.05,4.0,"Each single-dose prefilled syringe or single-dose vial is designed to deliver 0.05 mL (50 microliters) of solution containing 6 mg faricimab-svoa, L-histidine (155 mcg), L-methionine (52.2 mcg), polysorbate 20 (20 mcg), sodium chloride (73.1 mcg), D-sucrose (2.74 mg) and Water for Injection, adjusted to pH 5.5 with acetic acid.",6.338309288024903,25.4719767,-0.3252173913043478,0.1521739130434782,37.0691304347826,3.463239063333789,1.4323526924675738,-0.424956417235516,0.3826086956521739,G1;G1,Kappa;Lambda,VEGFA;ANGPT2,Bispecific mAb
fremanezumab,"AJOVY (FREMANEZUMAB-VFRM) INJECTION [TEVA PHARMACEUTICALS USA, INC.]",98e344ea-5916-4947-b6f2-4a76ccc04b6b,"Jun 11, 2026",subcutaneous,5.5,False,histidine,16.0,polysorbate 80,0.02,,148.0,1.5,4.0,"Each prefilled autoinjector or prefilled syringe delivers 1.5 mL of solution containing 225 mg fremanezumab-vfrm, disodium ethylenediaminetetraacetic acid dihydrate (EDTA) (0.204 mg), L-histidine (0.815 mg), L-histidine hydrochloride monohydrate (3.93 mg), polysorbate-80 (0.3 mg), sucrose (99 mg), and Water for Injection, and has a pH of 5.5.",7.845302772521974,25.1338185,-0.2235807860262008,0.131004366812227,41.43187772925764,3.789283949436342,1.9435937903270224,1.0985888704163909,0.4104803493449782,G2,Kappa,CALCA and CALCB,Whole mAb
glofitamab,"COLUMVI (GLOFITAMAB) CONCENTRATE COLUMVI (GLOFITAMAB) SOLUTION, CONCENTRATE [GENENTECH, INC.]",3516e753-f064-4d30-9bd5-e3f2e143f75d,"Jul 02, 2026",intravenous,5.5,False,,,,,,197.0,,0.0,"Each mL of solution contains 1 mg glofitamab-gxbm, histidine (0.63 mg), histidine hydrochloride monohydrate (3.34 mg), methionine (1.49 mg), polysorbate 20 (0.5 mg), sucrose (82.15 mg), and Water for Injection, USP, at pH 5.5.",9.0057336807251,25.1788522,-0.2055555555555556,0.1239316239316239,35.347435897435886,7.380272913642173,5.898653180256567,5.096404238438662,0.3974358974358974,G1;G1,Lambda;Kappa,CD3E;MS4A1/CD20,Bispecific mAb with Domain Crossover
golimumab,"SIMPONI ARIA (GOLIMUMAB) SOLUTION [JANSSEN BIOTECH, INC.]",9e260a47-55af-4c92-8d88-a86ccc767fff,"Sep 11, 2025",intravenous,5.5,False,,,,,,,,0.0,"Each 4-mL vial of SIMPONI ARIA contains 50 mg golimumab, L-histidine (1.14 mg), L-histidine monohydrochloride monohydrate (6.42 mg), polysorbate 80 (0.6 mg), sorbitol (180 mg), and water for injection.",8.823997306823731,25.635348799999992,-0.3115384615384615,0.1282051282051282,45.44658119658121,6.524564758257658,4.913047175968276,4.096419624151843,0.3974358974358974,G1,Kappa,TNF/TNFA,Whole mAb
guselkumab,"TREMFYA (GUSELKUMAB) INJECTION TREMFYA (GUSELKUMAB) INJECTION [JANSSEN BIOTECH, INC.]",1e6dc9ae-1c4c-42d9-87aa-c315ecc51b56,"Jun 08, 2026",subcutaneous,5.8,False,,,,,,147.0,,0.0,"Each TREMFYA 1 mL prefilled syringe, prefilled pen (TREMFYA PEN), or One-Press patient-controlled injector delivers 100 mg guselkumab, L-histidine (0.6 mg), L-histidine monohydrochloride monohydrate (1.5 mg), polysorbate 80 (0.5 mg), sucrose (79 mg) and water for injection at pH 5.8.",8.594876670837404,24.560215499999995,-0.2587719298245615,0.1184210526315789,41.51491228070174,5.339169647329274,3.892815896309931,3.0951889565381263,0.3684210526315789,G1,Lambda,IL23A,Whole mAb
guselkumab,"TREMFYA (GUSELKUMAB) INJECTION TREMFYA (GUSELKUMAB) INJECTION [JANSSEN BIOTECH, INC.]",1e6dc9ae-1c4c-42d9-87aa-c315ecc51b56,"Jun 08, 2026",subcutaneous,5.8,False,,,,,,147.0,,0.0,"Each TREMFYA 2 mL prefilled syringe or prefilled pen (TREMFYA PEN) delivers 200 mg guselkumab, L-histidine (1.2 mg), L-histidine monohydrochloride monohydrate (3 mg), polysorbate 80 (1 mg), sucrose (158 mg) and water for injection at pH 5.8.",8.594876670837404,24.560215499999995,-0.2587719298245615,0.1184210526315789,41.51491228070174,5.339169647329274,3.892815896309931,3.0951889565381263,0.3684210526315789,G1,Lambda,IL23A,Whole mAb
guselkumab,"TREMFYA (GUSELKUMAB) INJECTION TREMFYA (GUSELKUMAB) INJECTION [JANSSEN BIOTECH, INC.]",1e6dc9ae-1c4c-42d9-87aa-c315ecc51b56,"Jun 08, 2026",subcutaneous,5.8,False,,,,,,147.0,,0.0,"Each TREMFYA 20 mL vial delivers 200 mg guselkumab, EDTA disodium dihydrate (0.4 mg), L-histidine (11.3 mg), L-histidine monohydrochloride monohydrate (26.6 mg), L-methionine (8 mg), polysorbate 80 (10 mg), sucrose (1700 mg) and water for injection at pH 5.8.",8.594876670837404,24.560215499999995,-0.2587719298245615,0.1184210526315789,41.51491228070174,5.339169647329274,3.892815896309931,3.0951889565381263,0.3684210526315789,G1,Lambda,IL23A,Whole mAb
ibalizumab,"TROGARZO (IBALIZUMAB) INJECTION, SOLUTION [THERATECHNOLOGIES INC.]",c548ad82-9d1f-4d16-95b6-4e6106badf43,"Jan 12, 2026",intravenous,6.0,False,,,,,,150.0,,0.0,"Each single-dose vial delivers approximately 1.33 mL containing 200 mg of ibalizumab-uiyk, and contains the following inactive ingredients: 10 mM L-histidine (2.06 mg), 0.045% polysorbate 80 (0.60 mg), 52 mM sodium chloride (4.04 mg) and 5.2% sucrose (69.2 mg).",6.77721996307373,25.9955979,-0.4841880341880346,0.1324786324786324,34.2854700854701,2.8953367075159484,0.9533270074631032,0.0970534978394684,0.3717948717948718,G4,Kappa,CD4,Whole mAb
idarucizumab,"PRAXBIND (IDARUCIZUMAB) INJECTION [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]",c7400f8a-dcf4-a6df-6d07-983081b1bf34,"Feb 08, 2024",intravenous,5.5,True,acetate,25.0,polysorbate 20,0.02,,,50.0,4.0,"PRAXBIND (idarucizumab) is supplied in 2 single-dose vials, each containing 2.5 g of idarucizumab in 50 mL formulated as a buffered, isotonic, solution containing acetic acid glacial (10.05 mg), polysorbate 20 (10 mg), sodium acetate (88.82 mg), sorbitol (2004.20 mg), and water for injection with an osmolality of 270-330 mOsm/kg and a pH of 5.3-5.7.",8.577341270446777,25.469377200000004,-0.1209401709401708,0.1239316239316239,41.2440170940171,6.382089408621755,4.66029987000483,3.334800471781038,0.3888888888888889,G1,Kappa,Dabigatran,Fab
inebilizumab,"UPLIZNA (INEBILIZUMAB) INJECTION [HORIZON THERAPEUTICS USA, INC.]",834db232-afb0-4dcf-93e0-009ce8245c20,"Dec 24, 2025",intravenous,6.0,False,,,,,,,,0.0,"Each mL contains 10 mg of inebilizumab-cdon, L-histidine (1.4 mg), L-histidine hydrochloride monohydrate (2.3 mg), polysorbate 80 (0.1 mg), sodium chloride (4.1 mg), α,α-trehalose dihydrate (40.1 mg), and Water for Injection, USP and a pH of 6.",5.292415046691894,25.412979799999995,-0.3676724137931036,0.1163793103448275,38.064655172413794,0.2308744987978788,-2.00847003020902,-2.890133195193199,0.3448275862068966,G1,Kappa,CD19,Whole mAb
inotuzumab,"BESPONSA (INOTUZUMAB OZOGAMICIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [WYETH PHARMACEUTICALS LLC, A SUBSIDIARY OF PFIZER INC.]",cc7014b1-c775-411d-b374-8113248b4077,"Feb 09, 2026",intravenous,8.0,False,,,,,,160.0,,0.0,"Inactive ingredients are polysorbate 80 (0.36 mg), sodium chloride (2.16 mg), sucrose (180 mg), and tromethamine (8.64 mg).",8.966988182067873,25.6352148,-0.382403433476395,0.1330472103004291,32.860944206008575,9.354307924706587,7.421300964289161,5.575494578427029,0.3648068669527897,G4,Kappa,SIGLEC2/CD22,Whole mAb ADC
ipilimumab,"YERVOY (IPILIMUMAB) INJECTION [E.R. SQUIBB & SONS, L.L.C.]",2265ef30-253e-11df-8a39-0800200c9a66,"Aug 26, 2026",intravenous,7.0,False,,,,,,148.0,,0.0,"Each milliliter contains 5 mg of ipilimumab and the following inactive ingredients: diethylene triamine pentaacetic acid (DTPA) (0.04 mg), mannitol (10 mg), polysorbate 80 (vegetable origin) (0.1 mg), sodium chloride (5.85 mg), tris hydrochloride (3.15 mg), and Water for Injection, USP at a pH of 7.",8.847915077209475,24.830453899999984,-0.3101769911504425,0.1327433628318584,42.88938053097346,6.4892213338619085,4.909877712778525,4.09768012893086,0.3761061946902654,G1,Kappa,CTLA4/CD152,Whole mAb
isatuximab,"SARCLISA (ISATUXIMAB) INJECTION, SOLUTION, CONCENTRATE [SANOFI-AVENTIS U.S. LLC]",a0473462-6f9d-4eca-a5bf-8620aea68e8a,"Jul 09, 2026",intravenous,6.0,False,,,,,,148.0,,0.0,"Each mL of solution contains 20 mg isatuximab-irfc, histidine (1.46 mg), histidine hydrochloride monohydrate (2.22 mg), polysorbate 80 (0.2 mg), sucrose (100 mg), and water for injection.",6.983829689025879,24.77526959999999,-0.3687224669603524,0.1277533039647577,36.92158590308371,4.460365469081011,2.4310820436951257,0.5744377607308552,0.3744493392070485,G1,Kappa,ADPRC1/CD38,Whole mAb
isatuximab,"SARCLISA ESCENA (ISATUXIMAB-IRFC) INJECTION, SOLUTION [SANOFI-AVENTIS U.S. LLC]",07730e8c-1340-4d30-8d71-e20f850db8da,"Jul 13, 2026",subcutaneous,6.2,False,,,,,,148.0,,0.0,"Each mL of solution contains 140 mg isatuximab-irfc, arginine hydrochloride (23.2 mg), histidine (0.82 mg), histidine hydrochloride monohydrate (0.78 mg), poloxamer 188 (4.0 mg), sucrose (20.0 mg), and Water for Injection, USP.",6.983829689025879,24.77526959999999,-0.3687224669603524,0.1277533039647577,36.92158590308371,4.460365469081011,2.4310820436951257,0.5744377607308552,0.3744493392070485,G1,Kappa,ADPRC1/CD38,Whole mAb
ixekizumab,"TALTZ (IXEKIZUMAB) INJECTION, SOLUTION [ELI LILLY AND COMPANY]",ac96658a-d7dc-4c7c-8928-2adcdf4318b2,"Jun 23, 2026",subcutaneous,5.7,True,,,,,80.0,146.158,,0.0,"Each TALTZ 80 mg/mL single-dose autoinjector or TALTZ 80 mg/mL single-dose prefilled syringe is composed of ixekizumab (80 mg); Polysorbate 80, USP (0.3 mg); Sucrose, USP (80 mg); and Water for Injection, USP.",8.803174018859863,25.542386600000007,-0.3251082251082252,0.1168831168831168,37.63463203463203,10.440182535206878,7.9566197631194,5.058223354261256,0.3636363636363636,G4,Kappa,IL17A,Whole mAb
ixekizumab,"TALTZ (IXEKIZUMAB) INJECTION, SOLUTION [ELI LILLY AND COMPANY]",ac96658a-d7dc-4c7c-8928-2adcdf4318b2,"Jun 23, 2026",subcutaneous,5.7,True,,,polysorbate 80,0.03,80.0,146.158,0.5,2.0,"Each TALTZ 40 mg/0.5 mL single-dose prefilled syringe is composed of ixekizumab (40 mg); Polysorbate 80, USP (0.15 mg); Sucrose, USP (40 mg); and Water for Injection, USP.",8.803174018859863,25.542386600000007,-0.3251082251082252,0.1168831168831168,37.63463203463203,10.440182535206878,7.9566197631194,5.058223354261256,0.3636363636363636,G4,Kappa,IL17A,Whole mAb
ixekizumab,"TALTZ (IXEKIZUMAB) INJECTION, SOLUTION [ELI LILLY AND COMPANY]",ac96658a-d7dc-4c7c-8928-2adcdf4318b2,"Jun 23, 2026",subcutaneous,5.7,True,,,polysorbate 80,0.032,80.0,146.158,0.25,2.0,"Each TALTZ 20 mg/0.25 mL single-dose prefilled syringe is composed of ixekizumab (20 mg); Polysorbate 80, USP (0.08 mg); Sucrose, USP (20 mg); and Water for Injection, USP.",8.803174018859863,25.542386600000007,-0.3251082251082252,0.1168831168831168,37.63463203463203,10.440182535206878,7.9566197631194,5.058223354261256,0.3636363636363636,G4,Kappa,IL17A,Whole mAb
lanadelumab,"TAKHZYRO (LANADELUMAB-FLYO) SOLUTION TAKHZYRO (LANADELUMAB-FLYO) INJECTION, SOLUTION [TAKEDA PHARMACEUTICALS AMERICA, INC.]",15f99d8c-efe7-4f7d-aa20-0d0f1e30c6e8,"Aug 31, 2026",subcutaneous,6.0,False,,,,,,,,0.0,"Each mL of ready-to-use TAKHZYRO solution contains 150 mg of lanadelumab-flyo, citric acid monohydrate (4.1 mg), L-histidine (7.8 mg), polysorbate 80 (0.1 mg), sodium chloride (5.3 mg), sodium phosphate dibasic dihydrate (5.3 mg), and Water for Injection, USP.",8.840372276306152,25.0889586,-0.2521929824561403,0.1184210526315789,40.63070175438596,6.562813695040147,4.917806442009444,4.098953758346132,0.3815789473684211,G1,Kappa,KLKB1,Whole mAb
lecanemab,"LEQEMBI (LECANEMAB) INJECTION, SOLUTION LECANEMAB AUTOINJECTOR (LECANEMAB-IRMB) INJECTION, SOLUTION [EISAI INC.]",9d1ff786-e577-410a-a273-c4d7d0e4e975,"Jul 27, 2026",subcutaneous,5.0,False,,,,,,150.0,,0.0,"Each mL of solution contains 100 mg of lecanemab-irmb and arginine hydrochloride (42.13 mg), histidine (0.18 mg), histidine hydrochloride monohydrate (4.99 mg), polysorbate 80 (0.50 mg), and Water for Injection at an approximate pH of 5.0.",8.613572502136233,25.693461000000003,-0.2521186440677966,0.1271186440677966,45.318220338983046,7.539712803870183,5.4416299158470105,3.5777009206532577,0.3686440677966102,G1,Kappa,APP,Whole mAb
lecanemab,"LEQEMBI (LECANEMAB) INJECTION, SOLUTION LECANEMAB AUTOINJECTOR (LECANEMAB-IRMB) INJECTION, SOLUTION [EISAI INC.]",9d1ff786-e577-410a-a273-c4d7d0e4e975,"Jul 27, 2026",subcutaneous,5.0,False,histidine,24.99,polysorbate 80,0.05,200.0,150.0,1.8,4.0,"Each 360 mg/1.8 mL LEQEMBI IQLIK autoinjector contains 360 mg of lecanemab-irmb formulated in: arginine hydrochloride (75.83 mg), histidine (0.25 mg), histidine hydrochloride monohydrate (9.09 mg), polysorbate 80 (0.90 mg), and Water for Injection, USP.",8.613572502136233,25.693461000000003,-0.2521186440677966,0.1271186440677966,45.318220338983046,7.539712803870183,5.4416299158470105,3.5777009206532577,0.3686440677966102,G1,Kappa,APP,Whole mAb
lecanemab,"LEQEMBI (LECANEMAB) INJECTION, SOLUTION LECANEMAB AUTOINJECTOR (LECANEMAB-IRMB) INJECTION, SOLUTION [EISAI INC.]",9d1ff786-e577-410a-a273-c4d7d0e4e975,"Jul 27, 2026",subcutaneous,5.0,False,histidine,25.01,polysorbate 80,0.0504,200.0,150.0,1.25,4.0,"Each 250 mg/1.25 mL LEQEMBI IQLIK autoinjector contains 250 mg of lecanemab-irmb formulated in: arginine hydrochloride (52.66 mg), histidine (0.18 mg), histidine hydrochloride monohydrate (6.31 mg), polysorbate 80 (0.63 mg), and Water for Injection, USP.",8.613572502136233,25.693461000000003,-0.2521186440677966,0.1271186440677966,45.318220338983046,7.539712803870183,5.4416299158470105,3.5777009206532577,0.3686440677966102,G1,Kappa,APP,Whole mAb
loncastuximab,"ZYNLONTA (LONCASTUXIMAB TESIRINE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ADC THERAPEUTICS AMERICA, INC.]",af54af12-3edf-4301-8bc5-0446bc813c1d,"Jun 17, 2026",intravenous,6.0,False,,,,,,151.0,,0.0,"Each single-dose vial delivers 10 mg of loncastuximab tesirine-lpyl, L-histidine (2.8 mg), L-histidine monohydrochloride (4.6 mg), polysorbate 20 (0.4 mg), and sucrose (119.8 mg).",7.78083438873291,24.4869134,-0.4883928571428572,0.1205357142857143,46.47232142857141,5.539700264092766,3.44150452442872,1.5764476416003017,0.3571428571428571,G1,Kappa,CD19,Whole mAb ADC
margetuximab,"MARGENZA (MARGETUXIMAB-CMKB) INJECTION, SOLUTION, CONCENTRATE [TERSERA THERAPEUTICS LLC]",6a6d50c7-06ea-479c-83cc-f197a9e428c9,"Feb 24, 2025",intravenous,6.1,False,,,,,,149.0,,0.0,"Each mL of solution contains 25 mg of margetuximab-cmkb, L-arginine hydrochloride (11 mg), polysorbate 80 (0.1 mg), sodium chloride (2.9 mg), sodium phosphate dibasic, heptahydrate (0.58 mg), sodium phosphate monobasic, monohydrate (1.1 mg), sucrose (30 mg), and Water for Injection, USP at a pH of approximately 6.1.",8.28633098602295,25.2127946,-0.457709251101322,0.1277533039647577,41.29651982378856,7.541551543616839,5.203499036457733,2.8183197831257774,0.3612334801762114,G1,Kappa,ERBB2/CD340/HER2,Whole mAb
margetuximab,"MARGENZA (MARGETUXIMAB-CMKB) INJECTION, SOLUTION, CONCENTRATE [MACROGENICS, INC]",e97a5872-eabf-463b-8f4c-5b5aed9c7bf0,"Jan 27, 2025",intravenous,6.1,False,,,,,,149.0,,0.0,"Each mL of solution contains 25 mg of margetuximab-cmkb, L-arginine hydrochloride (11 mg), polysorbate 80 (0.1 mg), sodium chloride (2.9 mg), sodium phosphate dibasic, heptahydrate (0.58 mg), sodium phosphate monobasic, monohydrate (1.1 mg), sucrose (30 mg), and Water for Injection, USP at a pH of approximately 6.1.",8.28633098602295,25.2127946,-0.457709251101322,0.1277533039647577,41.29651982378856,7.541551543616839,5.203499036457733,2.8183197831257774,0.3612334801762114,G1,Kappa,ERBB2/CD340/HER2,Whole mAb
marstacimab,"HYMPAVZI (MARSTACIMAB-HNCQ) INJECTION, SOLUTION [PFIZER LABORATORIES DIV PFIZER INC]",a2cc631e-13a6-40c2-acf9-065ccedfb90a,"Jun 23, 2026",subcutaneous,5.8,False,histidine,24.43,polysorbate 80,0.02,,,1.0,5.0,"Each 1 mL of HYMPAVZI contains 150 mg of marstacimab‑hncq, and the inactive ingredients edetate disodium (0.05 mg), histidine (1.12 mg), L-histidine monohydrochloride (2.67 mg), polysorbate 80 (0.2 mg), and sucrose (85 mg), in Water for Injection, USP.",5.8035680770874025,24.102437899999988,-0.111206896551724,0.0948275862068965,45.33836206896551,1.3391949798663088,-0.1069307910321566,-0.9022791872146838,0.3706896551724138,G1,Lambda,ERBB2/CD340/HER2,Whole mAb
marstacimab,"HYMPAVZI (MARSTACIMAB-HNCQ) INJECTION, SOLUTION [PFIZER LABORATORIES DIV PFIZER INC]",a2cc631e-13a6-40c2-acf9-065ccedfb90a,"Jun 23, 2026",subcutaneous,5.8,False,histidine,24.49,polysorbate 80,0.02,,,0.5,5.0,"Each 0.5 mL of HYMPAVZI contains 75 mg of marstacimab‑hncq, and the inactive ingredients edetate disodium (0.03 mg), histidine (0.56 mg), L‑histidine monohydrochloride (1.34 mg), polysorbate 80 (0.1 mg), and sucrose (43 mg), in Water for Injection, USP.",5.8035680770874025,24.102437899999988,-0.111206896551724,0.0948275862068965,45.33836206896551,1.3391949798663088,-0.1069307910321566,-0.9022791872146838,0.3706896551724138,G1,Lambda,ERBB2/CD340/HER2,Whole mAb
mepolizumab,"NUCALA (MEPOLIZUMAB) INJECTION, POWDER, FOR SOLUTION NUCALA (MEPOLIZUMAB) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC]",fefb887c-e4ac-431e-8893-e9d1a5a63fea,"Aug 18, 2025",subcutaneous,6.3,False,phosphate,15.52,polysorbate 80,0.02,,149.0,1.0,4.0,"Each 1 mL delivers 100 mg mepolizumab, citric acid monohydrate (0.95 mg), EDTA disodium dihydrate (0.019 mg), polysorbate 80 (0.20 mg), sodium phosphate dibasic heptahydrate (4.16 mg), and sucrose (120 mg), with a pH of 6.3.",8.343643379211429,25.1820575,-0.2564655172413793,0.0905172413793103,31.345258620689656,5.455727730590652,3.668688177847709,2.340666960101628,0.3577586206896552,G1,Kappa,IL5,Whole mAb
mepolizumab,"NUCALA (MEPOLIZUMAB) INJECTION, POWDER, FOR SOLUTION NUCALA (MEPOLIZUMAB) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC]",fefb887c-e4ac-431e-8893-e9d1a5a63fea,"Aug 18, 2025",subcutaneous,6.3,False,phosphate,15.48,polysorbate 80,0.02,,149.0,0.4,4.0,"Each 0.4 mL delivers 40 mg mepolizumab, citric acid monohydrate (0.38 mg), EDTA disodium dihydrate (0.0074 mg), polysorbate 80 (0.08 mg), sodium phosphate dibasic heptahydrate (1.66 mg), and sucrose (48 mg), with a pH of 6.3.",8.343643379211429,25.1820575,-0.2564655172413793,0.0905172413793103,31.345258620689656,5.455727730590652,3.668688177847709,2.340666960101628,0.3577586206896552,G1,Kappa,IL5,Whole mAb
mepolizumab,"NUCALA (MEPOLIZUMAB) INJECTION, POWDER, FOR SOLUTION NUCALA (MEPOLIZUMAB) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC]",fefb887c-e4ac-431e-8893-e9d1a5a63fea,"Aug 18, 2025",subcutaneous,7.0,False,,,,,,149.0,,0.0,"Each vial delivers 100 mg of mepolizumab, polysorbate 80 (0.67 mg), sodium phosphate dibasic heptahydrate (7.14 mg), and sucrose (160 mg), with a pH of 7.0.",8.343643379211429,25.1820575,-0.2564655172413793,0.0905172413793103,31.345258620689656,5.455727730590652,3.668688177847709,2.340666960101628,0.3577586206896552,G1,Kappa,IL5,Whole mAb
natalizumab,TYRUKO (NATALIZUMAB-SZTN) INJECTION [SANDOZ INC],ef653c36-dd4b-4e71-9d2d-40b8fea24b67,"Jan 23, 2026",intravenous,5.7,False,histidine,10.0,,,,,15.0,3.0,"Each 15 mL of solution contains 300 mg natalizumab-sztn; histidine (6.36 mg); L-histidine hydrochloride monohydrate (22.86 mg); polysorbate 80, USP/NF (3 mg); sodium chloride, USP (131.49 mg); and Water for Injection, USP at pH 5.7.",8.552134132385255,25.435207200000004,-0.4480349344978167,0.1222707423580786,43.77379912663755,6.641062756060282,4.688318638795061,3.3358930255527115,0.3799126637554585,G4,Kappa,ITGA4/CD49D,Whole mAb
natalizumab,TYSABRI (NATALIZUMAB) INJECTION [BIOGEN INC.],c5fdde91-1989-4dd2-9129-4f3323ea2962,"Dec 25, 2025",intravenous,6.1,False,phosphate,10.01,,,,,15.0,3.0,"Each 15 mL of solution contains 300 mg natalizumab; sodium chloride, USP (123 mg); sodium phosphate, monobasic, monohydrate, USP (17 mg); sodium phosphate, dibasic, heptahydrate, USP (7.24 mg); polysorbate 80, USP/NF (3 mg), in Water for Injection, USP at pH 6.1.",8.552134132385255,25.435207200000004,-0.4480349344978167,0.1222707423580786,43.77379912663755,6.641062756060282,4.688318638795061,3.3358930255527115,0.3799126637554585,G4,Kappa,ITGA4/CD49D,Whole mAb
nemolizumab,"NEMLUVIO (NEMOLIZUMAB-ILTO) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [GALDERMA LABORATORIES, L.P.]",e9229ef1-ac60-4c24-afb6-009d3c781687,"Dec 16, 2025",subcutaneous,7.0,True,,,,,,144.0,,0.0,"One chamber contains 30 mg of nemolizumab-ilto with inactive ingredients arginine hydrochloride (9.5 mg), poloxamer 188 (0.15 mg), sucrose (25.8 mg), trometamol (0.10 mg), and tris hydrochloride for pH adjustment.",4.880957603454591,24.8452273,-0.4131578947368423,0.1140350877192982,37.163157894736834,-2.0616910223356872,-4.278663965030381,-5.658087920832534,0.3596491228070175,G2,Kappa,IL31RA,Whole mAb
obiltoxaximab,"ANTHIM (OBILTOXAXIMAB) SOLUTION [ELUSYS THERAPEUTICS, INC.]",39ad8799-00a4-4fc8-9852-c0536350c474,"Nov 25, 2025",intravenous,5.5,False,,,,,,148.0,,0.0,"Each mL contains 100 mg obiltoxaximab in L-histidine (6.2 mg), polysorbate 80 (0.1 mg), sorbitol (36 mg) with a pH of 5.5.",8.82393283843994,24.9235362,-0.474336283185841,0.1106194690265486,41.45663716814158,5.628824882638216,4.161372299126961,3.8588722738347054,0.3495575221238938,G1,Kappa,Anthrax Protective Antigen,Whole mAb
ocrelizumab,"OCREVUS ZUNOVO (OCRELIZUMAB AND HYALURONIDASE) INJECTION, SOLUTION [GENENTECH, INC.]",b216af61-99d0-42a3-afc2-b5bf86df1ec0,"Aug 20, 2026",subcutaneous,5.3,False,acetate,19.99,polysorbate 20,0.06,,61.0,23.0,5.0,"Each 23 mL of solution contains 920 mg ocrelizumab, 23,000 units of hyaluronidase (human recombinant), glacial acetic acid (5.5 mg), methionine (34.3 mg), polysorbate 20 (13.8 mg), sodium acetate (30.2 mg), trehalose (1889.5 mg), and water for injection at pH 5.3.",8.79672718048096,25.039688599999995,-0.3333333333333333,0.1359649122807017,36.88640350877192,7.234915881277292,5.644554350984909,4.333371540429062,0.3771929824561403,G1,Kappa,MS4A1/CD20,Whole mAb
ocrelizumab,"OCREVUS (OCRELIZUMAB) INJECTION [GENENTECH, INC.]",9da42362-3bb5-4b83-b4bb-b59fd4e55f0d,"May 20, 2026",intravenous,5.3,False,,,,,,,,0.0,"Each mL of solution contains 30 mg ocrelizumab, glacial acetic acid (0.25 mg), polysorbate 20 (0.2 mg), sodium acetate trihydrate (2.14 mg), and trehalose dihydrate (40 mg) at pH 5.3.",8.79672718048096,25.039688599999995,-0.3333333333333333,0.1359649122807017,36.88640350877192,7.234915881277292,5.644554350984909,4.333371540429062,0.3771929824561403,G1,Kappa,MS4A1/CD20,Whole mAb
odesivimab,"INMAZEB (ATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGN) INJECTION, SOLUTION [REGENERON PHARMACEUTICALS, INC.]",0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa,"Dec 22, 2025",intravenous,6.0,False,,,,,,145.0,,0.0,"Each mL contains 16.67 mg of atoltivimab, 16.67 mg of maftivimab, 16.67 mg of odesivimab, and L-histidine (0.74 mg), L-histidine monohydrochloride monohydrate (1.09 mg), polysorbate 80 (1 mg), sucrose (100 mg), and Water for Injection, USP with a pH of 6.0. 33.33 mg/33.33 mg/33.33 mg per mL:",6.852815818786621,25.244872300000004,-0.2623376623376622,0.1298701298701298,37.41428571428572,2.712833943689379,0.9345538978077929,0.0983031390591478,0.3896103896103896,G1,Kappa,Zaire Ebolavirus Glycoprotein,Whole mAb
odesivimab,"INMAZEB (ATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGN) INJECTION, SOLUTION [REGENERON PHARMACEUTICALS, INC.]",0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa,"Dec 22, 2025",intravenous,6.0,False,,,,,,145.0,14.5,2.0,"Each vial contains 483.3 mg of atoltivimab, 483.3 mg of maftivimab, and 483.3 mg of odesivimab in 14.5 mL.",6.852815818786621,25.244872300000004,-0.2623376623376622,0.1298701298701298,37.41428571428572,2.712833943689379,0.9345538978077929,0.0983031390591478,0.3896103896103896,G1,Kappa,Zaire Ebolavirus Glycoprotein,Whole mAb
odesivimab,"INMAZEB (ATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGN) INJECTION, SOLUTION [REGENERON PHARMACEUTICALS, INC.]",0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa,"Dec 22, 2025",intravenous,6.0,False,,,,,,145.0,,0.0,"Each mL contains 33.33 mg of atoltivimab, 33.33 mg of maftivimab, 33.33 mg of odesivimab, and L-histidine (0.74 mg), L-histidine monohydrochloride monohydrate (1.09 mg), polysorbate 80 (1 mg), sucrose (100 mg), and Water for Injection, USP with a pH of 6.0.",6.852815818786621,25.244872300000004,-0.2623376623376622,0.1298701298701298,37.41428571428572,2.712833943689379,0.9345538978077929,0.0983031390591478,0.3896103896103896,G1,Kappa,Zaire Ebolavirus Glycoprotein,Whole mAb
ofatumumab,"KESIMPTA (OFATUMUMAB) INJECTION, SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION]",6a8a3f53-2062-48ff-9dbe-b939df133ca3,"Apr 10, 2026",subcutaneous,5.5,False,acetate,50.01,polysorbate 80,0.02,,146.0,0.4,4.0,"Each 0.4 mL contains 20 mg of ofatumumab, and arginine (4 mg), disodium edetate (0.007 mg), polysorbate 80 (0.08 mg), sodium acetate trihydrate (2.722 mg), sodium chloride (1.192 mg), and Water for Injection, USP with a pH of 5.5.",8.347962760925295,25.133788899999992,-0.3117903930131004,0.1179039301310043,44.06375545851528,4.674624659757598,2.9301911318832987,2.099731169220384,0.388646288209607,G1,Kappa,MS4A1/CD20,Whole mAb
palivizumab,"SYNAGIS (PALIVIZUMAB) INJECTION, SOLUTION [SWEDISH ORPHAN BIOVITRUM AB (PUBL)]",3a0096c7-8139-44cd-bba4-520ab05c2cb2,"Jan 26, 2026",,6.0,False,,,,,,148.0,,0.0,"Each 100 mg single-dose vial of Synagis liquid solution contains 100 mg of palivizumab and also contains chloride (0.5 mg), glycine (0.1 mg), and histidine (3.9 mg), in a volume of 1 mL.",8.736062431335448,24.780801699999994,-0.2513274336283187,0.1150442477876106,31.0216814159292,6.40959922265067,4.89659101203449,4.067895031095968,0.3628318584070796,G1,Kappa,Respiratory Syncytial Virus Glycoprotein F,Whole mAb
palivizumab,"SYNAGIS (PALIVIZUMAB) INJECTION, SOLUTION [SWEDISH ORPHAN BIOVITRUM AB (PUBL)]",3a0096c7-8139-44cd-bba4-520ab05c2cb2,"Jan 26, 2026",,6.0,False,,,,,,148.0,,0.0,"Each 50 mg single-dose vial of Synagis liquid solution contains 50 mg of palivizumab and also contains chloride (0.2 mg), glycine (0.06 mg), and histidine (1.9 mg), in a volume of 0.5 mL.",8.736062431335448,24.780801699999994,-0.2513274336283187,0.1150442477876106,31.0216814159292,6.40959922265067,4.89659101203449,4.067895031095968,0.3628318584070796,G1,Kappa,Respiratory Syncytial Virus Glycoprotein F,Whole mAb
pertuzumab,"PHESGO (PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF) INJECTION, SOLUTION [GENENTECH, INC.]",27dd5e6b-72cd-458d-a015-cf4dab5800da,"May 25, 2026",subcutaneous,5.5,False,histidine,17.4,polysorbate 20,0.02667,,148.0,15.0,7.0,"PHESGO injection is supplied as two different configurations: PHESGO is supplied in a 15 mL single-dose vial containing 1,200 mg of pertuzumab, 600 mg of trastuzumab, and 30,000 units of hyaluronidase, and α,α-trehalose (397 mg), L-histidine (6.75 mg), L-histidine hydrochloric monohydrate (53.7 mg), L-methionine (22.4 mg), polysorbate 20 (6 mg), and sucrose (685 mg) with a pH of 5.5. PHESGO is supplied in a 10 mL single-dose vial containing 600 mg of pertuzumab, 600 mg of trastuzumab, and 20,000 units of hyaluronidase, and α,α-trehalose (397 mg), L-histidine (4.4 mg), L-histidine hydrochloric monohydrate (36.1 mg), L-methionine (14.9 mg), polysorbate 20 (4 mg), and sucrose (342 mg) with a pH of 5.5.",8.309281730651858,24.85748389999999,-0.2969026548672565,0.1371681415929203,32.340752212389376,3.5169789881193205,2.1486383389509927,1.85460492895036,0.3849557522123893,G1,Kappa,ERBB2/CD340/HER2,Whole mAb
pertuzumab,"PERJETA (PERTUZUMAB) INJECTION, SOLUTION, CONCENTRATE [GENENTECH, INC.]",17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,"May 04, 2026",intravenous,6.0,False,,,,,,148.0,,0.0,"Each single-dose vial contains 420 mg of pertuzumab,glacial acetic acid (9.2 mg), histidine (43.5 mg), polysorbate 20 (2.8 mg), and sucrose (575.1 mg) with a pH of 6.",8.309281730651858,24.85748389999999,-0.2969026548672565,0.1371681415929203,32.340752212389376,3.5169789881193205,2.1486383389509927,1.85460492895036,0.3849557522123893,G1,Kappa,ERBB2/CD340/HER2,Whole mAb
polatuzumab,"POLIVY (POLATUZUMAB VEDOTIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [GENENTECH, INC.]",20a16ab2-f338-4abb-9dcd-254bd949a2bc,"Aug 28, 2026",intravenous,5.3,False,,,,,,150.0,,0.0,"Each single-dose 30 mg POLIVY vial delivers 30 mg of polatuzumab vedotin-piiq, polysorbate-20 (1.8 mg), sodium hydroxide (0.82 mg), succinic acid (1.77 mg), and sucrose (62 mg).",4.846285820007323,24.759161399999986,-0.3464912280701754,0.1096491228070175,43.60701754385964,-2.8120866454929416,-4.776367800722689,-5.133879364823002,0.3596491228070175,G1,Kappa,AGM6/CD79B,Whole mAb ADC
polatuzumab,"POLIVY (POLATUZUMAB VEDOTIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [GENENTECH, INC.]",20a16ab2-f338-4abb-9dcd-254bd949a2bc,"Aug 28, 2026",intravenous,5.3,False,,,,,,150.0,,0.0,"Each single-dose 140 mg POLIVY vial delivers 140 mg of polatuzumab vedotin-piiq, polysorbate-20 (8.4 mg), sodium hydroxide (3.8 mg), succinic acid (8.27 mg), and sucrose (288 mg).",4.846285820007323,24.759161399999986,-0.3464912280701754,0.1096491228070175,43.60701754385964,-2.8120866454929416,-4.776367800722689,-5.133879364823002,0.3596491228070175,G1,Kappa,AGM6/CD79B,Whole mAb ADC
pozelimab,"VEOPOZ (POZELIMAB) INJECTION, SOLUTION [REGENERON PHARMACEUTICALS, INC.]",a8d6f10e-9430-450a-a3dd-b538f9b2a308,"Dec 10, 2025",subcutaneous,5.8,False,,,,,,145.0,,0.0,"Each mL contains 200 mg pozelimab-bbfg, arginine hydrochloride (21 mg), histidine (1.15 mg), L-histidine hydrochloride monohydrate (2.65 mg), polysorbate 80 (1.5 mg), sucrose (20 mg), and Water for Injection, USP.",8.308250236511231,24.711312199999995,-0.281057268722467,0.1145374449339207,35.210132158590305,3.443421683233626,2.1410601449328537,1.856833882615823,0.3656387665198238,G4,Kappa,C5,Whole mAb
ramucirumab,CYRAMZA (RAMUCIRUMAB) SOLUTION [ELI LILLY AND COMPANY],c6080942-dee6-423e-b688-1272c2ae90d4,"Jun 10, 2026",intravenous,6.0,False,,,,,9.98,147.0,,0.0,"CYRAMZA is formulated in glycine (9.98 mg/mL), histidine (0.65 mg/mL), histidine monohydrochloride (1.22 mg/mL), polysorbate 80 (0.1 mg/mL), sodium chloride (4.383 mg/mL), and Water for Injection, USP, pH 6.0.",8.641422843933107,24.034646799999987,-0.1677130044843049,0.116591928251121,38.29910313901345,4.3669811107282674,3.132114578925763,2.8574908264381293,0.3901345291479821,G1,Kappa,KDR/CD309/VEGFR2,Whole mAb
ranibizumab,"NUFYMCO (RANIBIZUMAB-LEYK) INJECTION, SOLUTION [ZYDUS PHARMACEUTICALS USA INC.]",05ed75bc-ae21-480b-9be4-cbc51689dd8a,"Jun 11, 2026",,5.5,False,,,,,10.0,48.0,0.05,0.0,"NUFYMCO is supplied as a sterile, preservative-free solution in a single-dose container designed to deliver 0.05 mL of 10 mg/mL ranibizumab-leyk (0.5 mg dose vial) or 6 mg/mL ranibizumab-leyk (0.3 mg dose vial) aqueous solution with 10 mM histidine HCl, 10% α,α- trehalose dihydrate, 0.01% polysorbate 20, pH 5.5.",6.338309288024903,25.4719767,-0.3252173913043478,0.1521739130434782,37.0691304347826,3.463239063333789,1.4323526924675738,-0.424956417235516,0.3826086956521739,G1,Kappa,VEGFA,Fab
ranibizumab,"BYOOVIZ (RANIBIZUMAB-NUNA) INJECTION, SOLUTION [HARROW EYE, LLC]",77b53b2c-da0e-44b2-ade4-b08ff75a7584,"Jan 02, 2026",,5.5,False,,,,,10.0,48.0,0.05,0.0,"BYOOVIZ is supplied as a preservative-free, sterile solution in a single-dose container designed to deliver 0.05 mL of 10 mg/mL BYOOVIZ (0.5 mg dose vial) aqueous solution with 10 mM histidine HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 20, pH 5.5.",6.338309288024903,25.4719767,-0.3252173913043478,0.1521739130434782,37.0691304347826,3.463239063333789,1.4323526924675738,-0.424956417235516,0.3826086956521739,G1,Kappa,VEGFA,Fab
ranibizumab,"SUSVIMO (RANIBIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.]",9c6d9e2a-9a77-4d11-b692-de87cfde3444,"Dec 04, 2025",,5.5,False,,,polysorbate 20,0.01,,48.0,0.1,2.0,"Each single-dose vial contains 10 mg of ranibizumab, histidine HCl (0.1 mg), polysorbate 20 (0.01 mg), sucrose (8.2 mg), and Water for Injection, in 0.1 mL of solution with a pH of 5.5.",6.338309288024903,25.4719767,-0.3252173913043478,0.1521739130434782,37.0691304347826,3.463239063333789,1.4323526924675738,-0.424956417235516,0.3826086956521739,G1,Kappa,VEGFA,Fab
ranibizumab,"BYOOVIZ (RANIBIZUMAB-NUNA) INJECTION, SOLUTION [BIOGEN INC.]",e46db299-edd1-4457-89b2-c1e2e505f1b0,"Dec 02, 2025",,5.5,False,,,,,10.0,48.0,0.05,0.0,"BYOOVIZ is supplied as a preservative-free, sterile solution in a single-dose container designed to deliver 0.05 mL of 10 mg/mL BYOOVIZ (0.5 mg dose vial) aqueous solution with 10 mM histidine HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 20, pH 5.5.",6.338309288024903,25.4719767,-0.3252173913043478,0.1521739130434782,37.0691304347826,3.463239063333789,1.4323526924675738,-0.424956417235516,0.3826086956521739,G1,Kappa,VEGFA,Fab
ravulizumab,"ULTOMIRIS (RAVULIZUMAB) SOLUTION, CONCENTRATE [ALEXION PHARMACEUTICALS INC.]",a9a590d9-0217-43c7-908d-e62a71279791,"Nov 17, 2025",intravenous,7.4,False,,,,,,148.0,,0.0,"Each mL also contains L-arginine (4.33 mg), polysorbate 80 (0.5 mg) (vegetable origin), sodium phosphate dibasic (4.42 mg), sodium phosphate monobasic (4.57 mg), sucrose (50 mg), and Water for Injection, USP.",5.710920524597168,25.0637023,-0.2943231441048035,0.1179039301310043,33.73930131004366,1.7557983210071162,-0.2975160018617224,-1.6576274383670118,0.37117903930131,G2,Kappa,C5,Whole mAb
reslizumab,"CINQAIR (RESLIZUMAB) INJECTION, SOLUTION, CONCENTRATE [TEVA RESPIRATORY, LLC]",053b9158-2a5b-48b9-bf47-5fa78a35ec33,"May 15, 2026",intravenous,5.5,False,,,,,,147.0,,0.0,"Each mL contains 10 mg of reslizumab, glacial acetic acid (0.12 mg), sodium acetate trihydrate (2.45 mg), and sucrose (70 mg), with a pH of 5.5.",6.558901405334471,24.2367156,-0.2609865470852018,0.116591928251121,33.1269058295964,1.5934513651244615,0.1579019272433486,-0.1428740614916098,0.3766816143497757,G4,Kappa,IL5,Whole mAb
romosozumab,"EVENITY (ROMOSOZUMAB-AQQG) INJECTION, SOLUTION [AMGEN, INC]",471baba2-7154-4488-9891-0db2f46791e7,"Aug 03, 2026",subcutaneous,5.2,False,,,polysorbate 20,0.00598,,149.0,1.17,3.0,"Each single-use prefilled syringe delivers 1.17 mL of solution containing 105 mg of romosozumab-aqqg, acetate (3.8 mg), calcium (0.61 mg), polysorbate 20 (0.07 mg) and sucrose (70 mg) in Water for Injection, USP, and sodium hydroxide to a pH of 5.2.",5.445993995666503,25.3248267,-0.4630434782608699,0.1217391304347826,37.15130434782608,0.8924963573966818,-1.047611218364703,-1.9002299324364609,0.3565217391304348,G2,Kappa,SOST,Whole mAb
rozanolixizumab,"RYSTIGGO (ROZANOLIXIZUMAB) INJECTION, SOLUTION [UCB, INC.]",3c0eb8c2-c042-4954-b451-3baa77f5e6d1,"Jan 21, 2026",subcutaneous,5.6,False,,,,,,148.0,,0.0,"Each mL also contains histidine (1.05 mg), L-histidine hydrochloride monohydrate (4.87 mg), polysorbate 80 (0.30 mg), proline (28.78 mg), and water for injection, USP.",8.622662544250488,24.92380080000001,-0.1646288209606986,0.1179039301310043,39.981222707423576,6.49393052970276,4.67298610102788,3.338591047295941,0.3755458515283842,G4,Kappa,FCGRT/FcRn,Whole mAb
sacituzumab,"TRODELVY (SACITUZUMAB GOVITECAN) POWDER, FOR SOLUTION [GILEAD SCIENCES, INC.]",57a597d2-03f0-472e-b148-016d7169169d,"Jun 29, 2026",intravenous,6.5,False,,,,,,160.0,,0.0,"Each single-dose vial of TRODELVY delivers 180 mg sacituzumab govitecan-hziy, 71.7 mg 2-(N-morpholino) ethane sulfonic acid (MES), 1.8 mg polysorbate 80 and 153.99 mg trehalose.",8.55999927520752,24.8675336,-0.2364035087719297,0.1403508771929824,25.50921052631577,5.336289694747922,3.891481669703824,3.093947900930689,0.3903508771929824,G1,Kappa,TACSTD2/TROP2/EGP1,Whole mAb ADC
sarilumab,"KEVZARA (SARILUMAB) INJECTION, SOLUTION [SANOFI-AVENTIS U.S. LLC]",827bc01c-d379-4266-a18c-c7f904b76af3,"Mar 11, 2026",subcutaneous,6.0,False,histidine,20.98,polysorbate 20,0.2,,150.0,1.14,3.0,"Each syringe or pen delivers 1.14 mL of solution containing 150 mg or 200 mg of sarilumab, arginine (8.94 mg), histidine (3.71 mg), polysorbate 20 (2.28 mg), sucrose (57 mg) and Water for Injection, USP.",7.882694435119628,24.22876149999999,-0.2914798206278026,0.1121076233183856,42.64439461883408,3.7100221650429823,1.9339013644484424,1.1038744092195083,0.3721973094170404,G1,Kappa,IL6R/CD126,Whole mAb
satralizumab,"ENSPRYNG (SATRALIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.]",64c156a4-9bad-4d45-a294-0733c141f47b,"Jun 24, 2026",subcutaneous,6.0,False,histidine,19.98,poloxamer 188,0.05,,143.0,1.0,2.0,"Each prefilled syringe or autoinjector delivers 1 mL of solution containing 120 mg satralizumab-mwge, L-arginine (26.1 mg), L-aspartic acid (pH adjustment), L-histidine (3.1 mg), poloxamer 188 (0.5 mg), and Water for Injection, USP.",5.169188117980955,24.51882469999999,-0.3150442477876107,0.0973451327433628,34.47300884955752,-0.2243383064792877,-3.0057635594873733,-5.934821717045377,0.3539823008849557,G2,Kappa,IL6R/CD126,Whole mAb
secukinumab,"COSENTYX (SECUKINUMAB) INJECTION COSENTYX (SECUKINUMAB) INJECTION, SOLUTION, CONCENTRATE [NOVARTIS PHARMACEUTICALS CORPORATION]",77c4b13e-7df3-42d4-81db-3d0cddb7f67a,"Aug 31, 2026",subcutaneous,5.8,False,histidine,14.8,polysorbate 80,0.02,150.0,,2.0,4.0,"Each COSENTYX UnoReady pen (300 mg/2 mL) contains 300 mg of secukinumab formulated in: L-histidine/histidine hydrochloride monohydrate (6.206 mg), L-methionine (1.492 mg), polysorbate 80 (0.4 mg), trehalose dihydrate (151.34 mg), and Sterile Water for Injection, USP, at pH of 5.8.",6.8484392166137695,26.0748231,-0.2782978723404256,0.1361702127659574,43.95106382978724,2.859681638246556,0.9470500682002828,0.0681092903022165,0.3957446808510638,G1,Kappa,IL17A,Whole mAb
secukinumab,"COSENTYX (SECUKINUMAB) INJECTION COSENTYX (SECUKINUMAB) INJECTION, SOLUTION, CONCENTRATE [NOVARTIS PHARMACEUTICALS CORPORATION]",77c4b13e-7df3-42d4-81db-3d0cddb7f67a,"Aug 31, 2026",subcutaneous,5.8,False,,,,,150.0,,,0.0,"Each COSENTYX Sensoready pen or prefilled syringe (150 mg/mL) contains 150 mg of secukinumab formulated in: L-histidine/histidine hydrochloride monohydrate (3.103 mg), L-methionine (0.746 mg), polysorbate 80 (0.2 mg), trehalose dihydrate (75.67 mg), and Sterile Water for Injection, USP, at pH of 5.8.",6.8484392166137695,26.0748231,-0.2782978723404256,0.1361702127659574,43.95106382978724,2.859681638246556,0.9470500682002828,0.0681092903022165,0.3957446808510638,G1,Kappa,IL17A,Whole mAb
secukinumab,"COSENTYX (SECUKINUMAB) INJECTION COSENTYX (SECUKINUMAB) INJECTION, SOLUTION, CONCENTRATE [NOVARTIS PHARMACEUTICALS CORPORATION]",77c4b13e-7df3-42d4-81db-3d0cddb7f67a,"Aug 31, 2026",subcutaneous,5.8,False,histidine,14.81,polysorbate 80,0.02,150.0,,0.5,4.0,"Each COSENTYX prefilled syringe (75 mg/0.5 mL) contains 75 mg of secukinumab formulated in: L-histidine/histidine hydrochloride monohydrate (1.552 mg), L-methionine (0.373 mg), polysorbate 80 (0.1 mg), trehalose dihydrate (37.83 mg), and Sterile Water for Injection, USP, at pH of 5.8.",6.8484392166137695,26.0748231,-0.2782978723404256,0.1361702127659574,43.95106382978724,2.859681638246556,0.9470500682002828,0.0681092903022165,0.3957446808510638,G1,Kappa,IL17A,Whole mAb
secukinumab,"COSENTYX (SECUKINUMAB) INJECTION COSENTYX (SECUKINUMAB) INJECTION, SOLUTION, CONCENTRATE [NOVARTIS PHARMACEUTICALS CORPORATION]",77c4b13e-7df3-42d4-81db-3d0cddb7f67a,"Aug 31, 2026",subcutaneous,5.8,False,histidine,20.0,polysorbate 80,0.02,25.0,,5.0,5.0,"Each COSENTYX vial (125 mg/5 mL) contains 125 mg of secukinumab formulated in: L-histidine (5.67 mg), L-histidine hydrochloride monohydrate (13.3 mg), L-methionine (3.73 mg), polysorbate 80 (1 mg), trehalose dihydrate (426 mg), and Sterile Water for Injection, USP, at pH of 5.8.",6.8484392166137695,26.0748231,-0.2782978723404256,0.1361702127659574,43.95106382978724,2.859681638246556,0.9470500682002828,0.0681092903022165,0.3957446808510638,G1,Kappa,IL17A,Whole mAb
spesolimab,"SPEVIGO (SPESOLIMAB-SBZO) INJECTION [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]",41a481ee-3062-45d1-aed5-17e8b105634d,"Jun 18, 2026",subcutaneous,5.5,True,acetate,44.95,polysorbate 20,0.04,,146.0,2.0,4.0,"Each 2 mL prefilled syringe contains 300 mg spesolimab-sbzo, arginine hydrochloride (10.6 mg), glacial acetic acid (0.64 mg), polysorbate 20 (0.80 mg), sodium acetate (6.50 mg), sucrose (102.8 mg), and Water for Injection, USP with a pH of 5.2 to 5.8.",8.836826515197757,25.126861000000005,-0.3603524229074891,0.1233480176211453,40.39784140969164,9.473722307771292,7.198270957138876,4.81984973235812,0.3656387665198238,G1,Kappa,IL36RN,Whole mAb
spesolimab,"SPEVIGO (SPESOLIMAB-SBZO) INJECTION [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]",41a481ee-3062-45d1-aed5-17e8b105634d,"Jun 18, 2026",subcutaneous,5.5,True,acetate,44.95,polysorbate 20,0.04,,146.0,1.0,4.0,"Each 1 mL prefilled syringe contains 150 mg spesolimab-sbzo, arginine hydrochloride (5.3 mg), glacial acetic acid (0.32 mg), polysorbate 20 (0.40 mg), sodium acetate (3.25 mg), sucrose (51.4 mg), and Water for Injection, USP with a pH of 5.2 to 5.8.",8.836826515197757,25.126861000000005,-0.3603524229074891,0.1233480176211453,40.39784140969164,9.473722307771292,7.198270957138876,4.81984973235812,0.3656387665198238,G1,Kappa,IL36RN,Whole mAb
spesolimab,"SPEVIGO (SPESOLIMAB-SBZO) INJECTION [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]",41a481ee-3062-45d1-aed5-17e8b105634d,"Jun 18, 2026",subcutaneous,5.5,True,acetate,45.15,polysorbate 20,0.04,,146.0,7.5,4.0,"Each 7.5 mL vial contains 450 mg spesolimab-sbzo, arginine hydrochloride (39.5 mg), glacial acetic acid (2.4 mg), polysorbate 20 (3.0 mg), sodium acetate (24.5 mg), sucrose (386 mg), and Water for Injection, USP with a pH of 5.2 to 5.8.",8.836826515197757,25.126861000000005,-0.3603524229074891,0.1233480176211453,40.39784140969164,9.473722307771292,7.198270957138876,4.81984973235812,0.3656387665198238,G1,Kappa,IL36RN,Whole mAb
spesolimab,SPEVIGO (SPESOLIMAB) INJECTION [LEO PHARMA INC.],78a4f7eb-8d34-4467-8d40-74ed24323806,"Mar 19, 2026",subcutaneous,5.5,True,acetate,44.95,polysorbate 20,0.04,,146.0,2.0,4.0,"Each 2 mL prefilled syringe contains 300 mg spesolimab-sbzo, arginine hydrochloride (10.6 mg), glacial acetic acid (0.64 mg), polysorbate 20 (0.80 mg), sodium acetate (6.50 mg), sucrose (102.8 mg), and Water for Injection, USP with a pH of 5.2 to 5.8.",8.836826515197757,25.126861000000005,-0.3603524229074891,0.1233480176211453,40.39784140969164,9.473722307771292,7.198270957138876,4.81984973235812,0.3656387665198238,G1,Kappa,IL36RN,Whole mAb
spesolimab,SPEVIGO (SPESOLIMAB) INJECTION [LEO PHARMA INC.],78a4f7eb-8d34-4467-8d40-74ed24323806,"Mar 19, 2026",subcutaneous,5.5,True,acetate,44.95,polysorbate 20,0.04,,146.0,1.0,4.0,"Each 1 mL prefilled syringe contains 150 mg spesolimab-sbzo, arginine hydrochloride (5.3 mg), glacial acetic acid (0.32 mg), polysorbate 20 (0.40 mg), sodium acetate (3.25 mg), sucrose (51.4 mg), and Water for Injection, USP with a pH of 5.2 to 5.8.",8.836826515197757,25.126861000000005,-0.3603524229074891,0.1233480176211453,40.39784140969164,9.473722307771292,7.198270957138876,4.81984973235812,0.3656387665198238,G1,Kappa,IL36RN,Whole mAb
spesolimab,SPEVIGO (SPESOLIMAB) INJECTION [LEO PHARMA INC.],78a4f7eb-8d34-4467-8d40-74ed24323806,"Mar 19, 2026",subcutaneous,5.5,True,acetate,45.15,polysorbate 20,0.04,,146.0,7.5,4.0,"Each 7.5 mL vial contains 450 mg spesolimab-sbzo, arginine hydrochloride (39.5 mg), glacial acetic acid (2.4 mg), polysorbate 20 (3.0 mg), sodium acetate (24.5 mg), sucrose (386 mg), and Water for Injection, USP with a pH of 5.2 to 5.8.",8.836826515197757,25.126861000000005,-0.3603524229074891,0.1233480176211453,40.39784140969164,9.473722307771292,7.198270957138876,4.81984973235812,0.3656387665198238,G1,Kappa,IL36RN,Whole mAb
sutimlimab,"ENJAYMO (SUTIMLIMAB-JOME) INJECTION, SOLUTION, CONCENTRATE [RECORDATI RARE DISEASES, INC.]",0a25363a-7781-d9f8-cb1c-be22987bf03b,"Mar 10, 2026",intravenous,6.1,False,,,,,,147.0,,0.0,"Each mL contains 50 mg of sutimlimab-jome and also contains polysorbate 80 (0.2 mg), sodium chloride (8.18 mg), sodium phosphate dibasic heptahydrate (0.48 mg), sodium phosphate monobasic monohydrate (1.13 mg), and Water for Injection, USP.",8.967246055603027,24.7194714,-0.2312775330396476,0.1233480176211453,48.07004405286342,9.16890466205645,7.4009881776397215,5.573449862672827,0.3832599118942731,G4,Kappa,C1S,Whole mAb
sutimlimab,"ENJAYMO (SUTIMLIMAB-JOME) INJECTION, SOLUTION, CONCENTRATE [BIOVERATIV THERAPEUTICS INC.]",281cf1d4-6296-4416-858e-9bff46d01b71,"May 13, 2024",intravenous,6.1,False,,,,,,147.0,,0.0,"Each mL contains 50 mg of sutimlimab-jome and also contains polysorbate 80 (0.2 mg), sodium chloride (8.18 mg), sodium phosphate dibasic heptahydrate (0.48 mg), sodium phosphate monobasic monohydrate (1.13 mg), and Water for Injection, USP.",8.967246055603027,24.7194714,-0.2312775330396476,0.1233480176211453,48.07004405286342,9.16890466205645,7.4009881776397215,5.573449862672827,0.3832599118942731,G4,Kappa,C1S,Whole mAb
tafasitamab,"MONJUVI (TAFASITAMAB-CXIX) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [INCYTE CORPORATION]",ec13ac6b-bfde-4e84-907a-83bd69584d95,"Feb 06, 2026",intravenous,6.0,False,,,,,,150.0,,0.0,"Each single-dose vial contains 200 mg tafasitamab-cxix, citric acid monohydrate (3.7 mg), polysorbate 20 (1 mg), sodium citrate dihydrate (31.6 mg) and trehalose dihydrate (378.3 mg).",6.981101417541503,25.783656600000008,-0.3223175965665236,0.1287553648068669,41.765665236051504,3.832207025767141,1.7111109094047654,0.3385313398950241,0.3776824034334764,G1,Kappa,CD19,Whole mAb
tafasitamab,"MONJUVI (TAFASITAMAB-CXIX) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [INCYTE CORPORATION]",9e0a220b-517f-4c86-b581-ffbab493fb58,"Nov 18, 2025",intravenous,6.0,False,,,,,,150.0,,0.0,"Each single-dose vial contains 200 mg tafasitamab-cxix, citric acid monohydrate (3.7 mg), polysorbate 20 (1 mg), sodium citrate dihydrate (31.6 mg) and trehalose dihydrate (378.3 mg).",6.981101417541503,25.783656600000008,-0.3223175965665236,0.1287553648068669,41.765665236051504,3.832207025767141,1.7111109094047654,0.3385313398950241,0.3776824034334764,G1,Kappa,CD19,Whole mAb
tebentafusp,"KIMMTRAK (TEBENTAFUSP) INJECTION, SOLUTION, CONCENTRATE [IMMUNOCORE COMMERCIAL LLC]",24a49f57-d2fc-4ffe-9eb1-fe0460c6b067,"Aug 24, 2026",intravenous,6.5,False,,,,,,77.0,,0.0,"Each single-dose vial contains tebentafusp-tebn (100 mcg), citric acid monohydrate (0.95 mg), di-sodium hydrogen phosphate (2.91 mg), mannitol (5 mg), polysorbate 20 (0.1 mg) trehalose (25 mg), and water for injection, with a pH of 6.5.",8.775839424133299,25.304974,-0.4000000000000001,0.1310043668122271,30.33668122270741,5.5552040319985005,4.153158692993624,3.85475164527482,0.3755458515283842,na,Kappa,CD3E,scFv Fusion
teprotumumab,"TEPEZZA (TEPROTUMUMAB) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [HORIZON THERAPEUTICS USA, INC.]",3e6c54a1-cefd-4a5b-a855-ab9f268b6cce,"Jul 01, 2026",intravenous,5.5,False,,,,,,148.0,,0.0,"Each single-dose vial delivers 500 mg of teprotumumab-trbw, histidine (7.82 mg), L-histidine hydrochloride monohydrate (33.43 mg), polysorbate 20 (1.05 mg), and trehalose (898.43 mg).",9.210872077941891,24.982702699999987,-0.3327433628318585,0.1238938053097345,50.38141592920353,8.712876576584794,6.934980197919949,6.102563258217439,0.3805309734513274,G1,Kappa,IGF1R/CD221,Whole mAb
tildrakizumab,"ILUMYA (TILDRAKIZUMAB-ASMN) INJECTION, SOLUTION [SUN PHARMACEUTICAL INDUSTRIES, INC.]",c6a322bb-51b9-4f0e-8642-62a9682ffcde,"Jul 30, 2026",subcutaneous,6.0,True,histidine,9.96,polysorbate 80,0.05,,,1.0,4.0,"Each 1 mL single-dose prefilled syringe contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3.",8.297032737731932,24.381089300000006,-0.2829596412556054,0.1255605381165919,36.61569506726456,5.570377492159463,3.681995561096298,2.338572499315106,0.3811659192825112,G1,Kappa,IL23A,Whole mAb
tisotumab,"TIVDAK (TISOTUMAB VEDOTIN) INJECTION, POWDER, FOR SOLUTION [SEAGEN INC.]",c9fe3f32-4219-466e-acb9-3f609b4f4df1,"Nov 21, 2025",,6.0,False,,,,,,153.0,,0.0,"Each mL of reconstituted solution contains 10 mg of tisotumab vedotin-tftv, d-mannitol (30 mg), l-histidine (2.11 mg), l-histidine monohydrochloride (3.44 mg), and sucrose (30 mg), at pH 6.0.",8.323722648620606,24.49488899999999,-0.3746666666666667,0.1244444444444444,48.45599999999998,3.4816291737722205,2.145404981699916,1.8552270378879063,0.3644444444444444,G1,Kappa,F3/CD142,Whole mAb
tocilizumab,"TYENNE (TOCILIZUMAB-AAZG) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]",ad76441d-da59-47df-8d9d-2243005180f0,"Aug 31, 2026",subcutaneous,6.0,False,,,,,,148.0,,0.0,"Each mL of solution contains arginine (17.4 mg), histidine (3.1 mg), lactic acid (0.9 mg), polysorbate 80 (0.2 mg), sodium chloride (0.6 mg), and Water for Injection, USP. It is supplied in a ready-to-use, single-dose 0.9 mL prefilled syringe (PFS) with a needle safety device or in a ready-to-use, single-dose 0.9 mL autoinjector that delivers 162 mg tocilizumab-aazg, arginine (16.7 mg), histidine (2.0 mg), lactic acid (0.9 mg), polysorbate 80 (0.2 mg), sodium chloride (0.6 mg), and Water for Injection, USP.",9.158588218688966,24.801471499999995,-0.3252212389380531,0.1061946902654867,35.139823008849554,9.084892412458071,7.627774698486712,6.333700692283307,0.3539823008849557,G1,Kappa,IL6R/CD126,Whole mAb
tocilizumab,"TYENNE (TOCILIZUMAB-AAZG) INJECTION, SOLUTION, CONCENTRATE [FRESENIUS KABI USA, LLC]",e400bbe6-43c5-4de6-82b9-cb44ce3cd906,"Aug 17, 2026",subcutaneous,6.0,False,,,,,,148.0,,0.0,"Each mL of solution contains arginine (17.4 mg), histidine (3.1 mg), lactic acid (0.9 mg), polysorbate 80 (0.2 mg), sodium chloride (0.6 mg), and Water for Injection, USP. It is supplied in a ready-to-use, single-dose 0.9 mL prefilled syringe (PFS) with a needle safety device or in a ready-to-use, single-dose 0.9 mL autoinjector that delivers 162 mg tocilizumab-aazg, arginine (16.7 mg), histidine (2.0 mg), lactic acid (0.9 mg), polysorbate 80 (0.2 mg), sodium chloride (0.6 mg), and Water for Injection, USP.",9.158588218688966,24.801471499999995,-0.3252212389380531,0.1061946902654867,35.139823008849554,9.084892412458071,7.627774698486712,6.333700692283307,0.3539823008849557,G1,Kappa,IL6R/CD126,Whole mAb
tocilizumab,"TYENNE (TOCILIZUMAB-AAZG) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]",87ac5047-4f2b-4571-a8a8-32e08865f379,"Aug 04, 2026",subcutaneous,6.0,False,,,,,,148.0,,0.0,"Each mL of solution contains arginine (17.4 mg), histidine (3.1 mg), lactic acid (0.9 mg), polysorbate 80 (0.2 mg), sodium chloride (0.6 mg), and Water for Injection, USP. It is supplied in a ready-to-use, single-dose 0.9 mL prefilled syringe (PFS) with a needle safety device or in a ready-to-use, single-dose 0.9 mL autoinjector that delivers 162 mg tocilizumab-aazg, arginine (16.7 mg), histidine (2.0 mg), lactic acid (0.9 mg), polysorbate 80 (0.2 mg), sodium chloride (0.6 mg), and Water for Injection, USP.",9.158588218688966,24.801471499999995,-0.3252212389380531,0.1061946902654867,35.139823008849554,9.084892412458071,7.627774698486712,6.333700692283307,0.3539823008849557,G1,Kappa,IL6R/CD126,Whole mAb
tocilizumab,"AVTOZMA (TOCILIZUMAB) INJECTION, SOLUTION [CELLTRION USA, INC.]",581c288f-8015-40ef-a4c3-683c96db193d,"Jul 29, 2026",subcutaneous,6.0,False,,,,,,148.0,,0.0,"Each mL of solution contains histidine (0.74 mg), L-histidine hydrochloride monohydrate (1.09 mg), methionine (8.95 mg), polysorbate 80 (0.5 mg), threonine (19.06 mg), and Water for Injection, USP. It is supplied in a ready-to-use, single-dose 0.9 mL prefilled syringe (PFS) with a needle safety device or a ready- to-use, single-dose 0.9 mL autoinjector that delivers 162 mg tocilizumab-anoh, histidine (0.7 mg), L-histidine hydrochloride monohydrate (1.0 mg), methionine (8.1 mg), polysorbate 80 (0.2 mg), threonine (17.2 mg), and Water for Injection, USP.",9.158588218688966,24.801471499999995,-0.3252212389380531,0.1061946902654867,35.139823008849554,9.084892412458071,7.627774698486712,6.333700692283307,0.3539823008849557,G1,Kappa,IL6R/CD126,Whole mAb
toripalimab,"LOQTORZI (TORIPALIMAB-TPZI) INJECTION [COHERUS ONCOLOGY, INC.]",82e7921a-1e84-4988-9799-0ad7d19b2a75,"Jul 27, 2026",intravenous,6.0,False,,,,,,150.0,,0.0,"Each mL of solution contains 40 mg toripalimab-tpzi, citric acid monohydrate (0.51 mg), mannitol (25 mg), polysorbate 80 (0.20 mg), sodium chloride (2.92 mg), sodium citrate (4.65 mg), and Water for Injection, USP, at pH 6.0.",7.062210655212403,25.9728064,-0.2662447257383964,0.1139240506329113,38.4493670886076,5.844516356539707,3.238771771474801,0.8226922093488939,0.3713080168776371,G4,Kappa,PDCD1/CD279/PD1,Whole mAb
tralokinumab,"ADBRY (TRALOKINUMAB-LDRM) INJECTION, SOLUTION [LEO PHARMA INC.]",d8020b69-3001-44e2-9b5d-5f93d9aaf6e1,"Dec 19, 2025",subcutaneous,5.5,False,acetate,49.09,polysorbate 80,0.01,,147.0,1.0,4.0,"Each prefilled syringe delivers 150 mg tralokinumab-ldrm in 1 mL and the inactive ingredients: acetic acid (0.3 mg), polysorbate 80 (0.1 mg), sodium acetate trihydrate (6 mg), sodium chloride (5 mg), and Water for Injection, at an approximate pH of 5.5.",5.864385795593261,24.861314299999982,-0.3269565217391306,0.108695652173913,32.27391304347826,1.7453656526842838,-0.0629285399064756,-0.8973797710241868,0.3652173913043478,G4,Lambda,IL13,Whole mAb
tralokinumab,"ADBRY (TRALOKINUMAB-LDRM) INJECTION, SOLUTION [LEO PHARMA INC.]",d8020b69-3001-44e2-9b5d-5f93d9aaf6e1,"Dec 19, 2025",subcutaneous,5.5,False,acetate,49.09,polysorbate 80,0.01,,147.0,2.0,4.0,"Each autoinjector delivers 300 mg tralokinumab-ldrm in 2 mL and the inactive ingredients: acetic acid (0.6 mg), polysorbate 80 (0.2 mg), sodium acetate trihydrate (12 mg), sodium chloride (10 mg), and Water for Injection, at an approximate pH of 5.5.",5.864385795593261,24.861314299999982,-0.3269565217391306,0.108695652173913,32.27391304347826,1.7453656526842838,-0.0629285399064756,-0.8973797710241868,0.3652173913043478,G4,Lambda,IL13,Whole mAb
trastuzumab,"OGIVRI (TRASTUZUMAB-DKST) KIT OGIVRI (TRASTUZUMAB-DKST) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [BIOCON BIOLOGICS INC.]",b6465b44-a6dd-f99c-d009-6851cf05169c,"Aug 17, 2026",intravenous,6.0,False,,,,,,,,0.0,"Each multiple-dose vial of Ogivri delivers 420 mg trastuzumab-dkst, D-sorbitol (322.6 mg), L-Histidine (6.0 mg), Histidine hydrochloride monohydrate (9.4 mg) and Polyethylene glycol 3350/Macrogol 3350 (94.1 mg).",8.61312122344971,24.8424384,-0.3343612334801762,0.1233480176211453,40.72339207048458,6.455687982871617,4.66829072904804,3.336695308943121,0.3788546255506608,G1,Kappa,ERBB2/CD340/HER2,Whole mAb
trastuzumab,"OGIVRI (TRASTUZUMAB-DKST) KIT OGIVRI (TRASTUZUMAB-DKST) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [BIOCON BIOLOGICS INC.]",b6465b44-a6dd-f99c-d009-6851cf05169c,"Aug 17, 2026",intravenous,6.0,False,,,,,,,,0.0,"Each single-dose vial of Ogivri delivers 150 mg trastuzumab-dkst, D-sorbitol (115.2 mg), L-Histidine (2.16 mg), L-Histidine hydrochloride monohydrate (3.36 mg) and Polyethylene glycol 3350/Macrogol 3350 (33.6 mg).",8.61312122344971,24.8424384,-0.3343612334801762,0.1233480176211453,40.72339207048458,6.455687982871617,4.66829072904804,3.336695308943121,0.3788546255506608,G1,Kappa,ERBB2/CD340/HER2,Whole mAb
trastuzumab,"KANJINTI (TRASTUZUMAB-ANNS) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [AMGEN, INC]",9a94f5b2-b84e-4987-8ea1-c4346db5a5fa,"Jun 26, 2026",intravenous,6.0,False,,,,,,,,0.0,"Each multiple-dose vial of KANJINTI delivers 420 mg trastuzumab-anns, 381.8 mg α,α-trehalose dihydrate, 9.5 mg L-histidine HCl monohydrate, 6.1 mg L-histidine, and 1.7 mg polysorbate 20.",8.61312122344971,24.8424384,-0.3343612334801762,0.1233480176211453,40.72339207048458,6.455687982871617,4.66829072904804,3.336695308943121,0.3788546255506608,G1,Kappa,ERBB2/CD340/HER2,Whole mAb
trastuzumab,"KANJINTI (TRASTUZUMAB-ANNS) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [AMGEN, INC]",9a94f5b2-b84e-4987-8ea1-c4346db5a5fa,"Jun 26, 2026",intravenous,6.0,False,,,,,,,,0.0,"Each single-dose vial of KANJINTI delivers 150 mg trastuzumab-anns, 136.2 mg α,α-trehalose dihydrate, 3.4 mg L-histidine HCl monohydrate, 2.2 mg L-histidine, and 0.6 mg polysorbate 20.",8.61312122344971,24.8424384,-0.3343612334801762,0.1233480176211453,40.72339207048458,6.455687982871617,4.66829072904804,3.336695308943121,0.3788546255506608,G1,Kappa,ERBB2/CD340/HER2,Whole mAb
trastuzumab,"HERCEPTIN (TRASTUZUMAB) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [GENENTECH, INC.]",492dbdb2-077e-4064-bff3-372d6af0a7a2,"Jun 03, 2026",intravenous,6.0,False,,,,,,,,0.0,"Each single-dose vial of Herceptin delivers 150 mg trastuzumab, 136.2 mg α,α-trehalose dihydrate, 3.4 mg L-histidine HCl monohydrate, 2.2 mg L-histidine, and 0.6 mg polysorbate 20.",8.61312122344971,24.8424384,-0.3343612334801762,0.1233480176211453,40.72339207048458,6.455687982871617,4.66829072904804,3.336695308943121,0.3788546255506608,G1,Kappa,ERBB2/CD340/HER2,Whole mAb
ustekinumab,"USTEKINUMAB-AEKN INJECTION, SOLUTION [TEVA PHARMACEUTICALS USA, INC.]",052a3fb2-21c3-4c4e-a01e-afdd1accd1cd,"Aug 03, 2026",subcutaneous,6.0,True,histidine,4.84,polysorbate 80,0.004,,,0.5,3.0,"Each 0.5 mL prefilled syringe or vial delivers 45 mg ustekinumab-aekn, histidine (0.122 mg), L-histidine monohydrochloride monohydrate (0.507 mg), polysorbate 80 (0.02 mg), sucrose (38 mg) and water for injection (q.s).",8.796211433410647,24.9427595,-0.3384955752212389,0.1283185840707964,51.72212389380531,5.443410570233012,4.140949021056975,3.855723256428932,0.3716814159292035,G1,Kappa,IL12B/CLMFp40,Whole mAb
ustekinumab,"USTEKINUMAB-AEKN INJECTION, SOLUTION [TEVA PHARMACEUTICALS USA, INC.]",052a3fb2-21c3-4c4e-a01e-afdd1accd1cd,"Aug 03, 2026",subcutaneous,6.0,True,histidine,4.83,polysorbate 80,0.004,,,1.0,3.0,"Each 1 mL prefilled syringe delivers 90 mg ustekinumab-aekn, histidine (0.243 mg), L-histidine monohydrochloride monohydrate (1.013 mg), polysorbate 80 (0.04 mg), sucrose (76 mg) and water for injection (q.s).",8.796211433410647,24.9427595,-0.3384955752212389,0.1283185840707964,51.72212389380531,5.443410570233012,4.140949021056975,3.855723256428932,0.3716814159292035,G1,Kappa,IL12B/CLMFp40,Whole mAb
ustekinumab,"USTEKINUMAB-AEKN INJECTION, SOLUTION [TEVA PHARMACEUTICALS USA, INC.]",052a3fb2-21c3-4c4e-a01e-afdd1accd1cd,"Aug 03, 2026",subcutaneous,6.0,True,histidine,9.92,polysorbate 80,0.04,,,26.0,4.0,"Each 26 mL vial delivers 130 mg ustekinumab-aekn, edetate disodium (0.47 mg), histidine (20.02 mg), L- histidine monohydrochloride monohydrate (27.04 mg), methionine (10.4 mg), polysorbate 80 (10.4 mg), sucrose (2,210 mg), and water for injection (q.s).",8.796211433410647,24.9427595,-0.3384955752212389,0.1283185840707964,51.72212389380531,5.443410570233012,4.140949021056975,3.855723256428932,0.3716814159292035,G1,Kappa,IL12B/CLMFp40,Whole mAb
ustekinumab,"USTEKINUMAB-AEKN INJECTION, SOLUTION [TEVA PHARMACEUTICALS USA, INC.]",183a1dff-ef33-4ddb-ba38-f7861b0f77ad,"Aug 03, 2026",subcutaneous,6.0,True,histidine,4.84,polysorbate 80,0.004,,,0.5,3.0,"Each 0.5 mL prefilled syringe or vial delivers 45 mg ustekinumab-aekn, histidine (0.122 mg), L-histidine monohydrochloride monohydrate (0.507 mg), polysorbate 80 (0.02 mg), sucrose (38 mg) and water for injection (q.s).",8.796211433410647,24.9427595,-0.3384955752212389,0.1283185840707964,51.72212389380531,5.443410570233012,4.140949021056975,3.855723256428932,0.3716814159292035,G1,Kappa,IL12B/CLMFp40,Whole mAb
ustekinumab,"USTEKINUMAB-AEKN INJECTION, SOLUTION [TEVA PHARMACEUTICALS USA, INC.]",183a1dff-ef33-4ddb-ba38-f7861b0f77ad,"Aug 03, 2026",subcutaneous,6.0,True,histidine,4.83,polysorbate 80,0.004,,,1.0,3.0,"Each 1 mL prefilled syringe delivers 90 mg ustekinumab-aekn, histidine (0.243 mg), L-histidine monohydrochloride monohydrate (1.013 mg), polysorbate 80 (0.04 mg), sucrose (76 mg) and water for injection (q.s).",8.796211433410647,24.9427595,-0.3384955752212389,0.1283185840707964,51.72212389380531,5.443410570233012,4.140949021056975,3.855723256428932,0.3716814159292035,G1,Kappa,IL12B/CLMFp40,Whole mAb
ustekinumab,"USTEKINUMAB-AEKN INJECTION, SOLUTION [TEVA PHARMACEUTICALS USA, INC.]",183a1dff-ef33-4ddb-ba38-f7861b0f77ad,"Aug 03, 2026",subcutaneous,6.0,True,histidine,9.92,polysorbate 80,0.04,,,26.0,4.0,"Each 26 mL vial delivers 130 mg ustekinumab-aekn, edetate disodium (0.47 mg), histidine (20.02 mg), L- histidine monohydrochloride monohydrate (27.04 mg), methionine (10.4 mg), polysorbate 80 (10.4 mg), sucrose (2,210 mg), and water for injection (q.s).",8.796211433410647,24.9427595,-0.3384955752212389,0.1283185840707964,51.72212389380531,5.443410570233012,4.140949021056975,3.855723256428932,0.3716814159292035,G1,Kappa,IL12B/CLMFp40,Whole mAb
ustekinumab,"USTEKINUMAB INJECTION, SOLUTION USTEKINUMAB SOLUTION [JANSSEN BIOTECH, INC.]",23b486eb-f48d-47d4-815e-1313d4ebfbfa,"Jul 27, 2026",subcutaneous,6.0,True,histidine,4.77,polysorbate 80,0.004,,,0.5,3.0,"Each 0.5 mL prefilled syringe or vial delivers 45 mg ustekinumab, L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg).",8.796211433410647,24.9427595,-0.3384955752212389,0.1283185840707964,51.72212389380531,5.443410570233012,4.140949021056975,3.855723256428932,0.3716814159292035,G1,Kappa,IL12B/CLMFp40,Whole mAb
ustekinumab,"USTEKINUMAB INJECTION, SOLUTION USTEKINUMAB SOLUTION [JANSSEN BIOTECH, INC.]",23b486eb-f48d-47d4-815e-1313d4ebfbfa,"Jul 27, 2026",subcutaneous,6.0,True,histidine,4.77,polysorbate 80,0.004,,,1.0,3.0,"Each 1 mL prefilled syringe delivers 90 mg ustekinumab, L-histidine and L-histidine monohydrochloride monohydrate (1 mg), Polysorbate 80 (0.04 mg), and sucrose (76 mg).",8.796211433410647,24.9427595,-0.3384955752212389,0.1283185840707964,51.72212389380531,5.443410570233012,4.140949021056975,3.855723256428932,0.3716814159292035,G1,Kappa,IL12B/CLMFp40,Whole mAb
ustekinumab,"USTEKINUMAB INJECTION, SOLUTION USTEKINUMAB SOLUTION [JANSSEN BIOTECH, INC.]",23b486eb-f48d-47d4-815e-1313d4ebfbfa,"Jul 27, 2026",subcutaneous,6.0,True,histidine,9.91,polysorbate 80,0.04,,,26.0,5.0,"Each 26 mL vial delivers 130 mg ustekinumab, EDTA disodium salt dihydrate (0.52 mg), L-histidine (20 mg), L-histidine hydrochloride monohydrate (27 mg), L-methionine (10.4 mg), Polysorbate 80 (10.4 mg), and sucrose (2210 mg).",8.796211433410647,24.9427595,-0.3384955752212389,0.1283185840707964,51.72212389380531,5.443410570233012,4.140949021056975,3.855723256428932,0.3716814159292035,G1,Kappa,IL12B/CLMFp40,Whole mAb
ustekinumab,"STELARA (USTEKINUMAB) INJECTION, SOLUTION STELARA (USTEKINUMAB) SOLUTION [JANSSEN BIOTECH, INC.]",c77a9664-e3bb-4023-b400-127aa53bca2b,"Jul 23, 2026",subcutaneous,6.0,True,histidine,4.77,polysorbate 80,0.004,,,0.5,3.0,"Each 0.5 mL prefilled syringe or vial delivers 45 mg ustekinumab, L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg).",8.796211433410647,24.9427595,-0.3384955752212389,0.1283185840707964,51.72212389380531,5.443410570233012,4.140949021056975,3.855723256428932,0.3716814159292035,G1,Kappa,IL12B/CLMFp40,Whole mAb
ustekinumab,"STELARA (USTEKINUMAB) INJECTION, SOLUTION STELARA (USTEKINUMAB) SOLUTION [JANSSEN BIOTECH, INC.]",c77a9664-e3bb-4023-b400-127aa53bca2b,"Jul 23, 2026",subcutaneous,6.0,True,histidine,4.77,polysorbate 80,0.004,,,1.0,3.0,"Each 1 mL prefilled syringe delivers 90 mg ustekinumab, L-histidine and L-histidine monohydrochloride monohydrate (1 mg), Polysorbate 80 (0.04 mg), and sucrose (76 mg).",8.796211433410647,24.9427595,-0.3384955752212389,0.1283185840707964,51.72212389380531,5.443410570233012,4.140949021056975,3.855723256428932,0.3716814159292035,G1,Kappa,IL12B/CLMFp40,Whole mAb
ustekinumab,"STELARA (USTEKINUMAB) INJECTION, SOLUTION STELARA (USTEKINUMAB) SOLUTION [JANSSEN BIOTECH, INC.]",c77a9664-e3bb-4023-b400-127aa53bca2b,"Jul 23, 2026",subcutaneous,6.0,True,histidine,9.91,polysorbate 80,0.04,,,26.0,5.0,"Each 26 mL vial delivers 130 mg ustekinumab, EDTA disodium salt dihydrate (0.52 mg), L-histidine (20 mg), L-histidine hydrochloride monohydrate (27 mg), L-methionine (10.4 mg), Polysorbate 80 (10.4 mg), and sucrose (2210 mg).",8.796211433410647,24.9427595,-0.3384955752212389,0.1283185840707964,51.72212389380531,5.443410570233012,4.140949021056975,3.855723256428932,0.3716814159292035,G1,Kappa,IL12B/CLMFp40,Whole mAb
vedolizumab,"ENTYVIO (VEDOLIZUMAB) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION ENTYVIO PEN (VEDOLIZUMAB) INJECTION, SOLUTION ENTYVIO (VEDOLIZUMAB) INJECTION, SOLUTION [TAKEDA PHARMACEUTICALS AMERICA, INC.]",6e94621c-1a95-4af9-98d1-52b9e6f1949c,"May 13, 2026",subcutaneous,6.5,False,,,,,,147.0,,0.0,"Each single-dose vial contains 300 mg vedolizumab, arginine hydrochloride (131.7 mg), histidine (23 mg), histidine monohydrochloride (21.4 mg), polysorbate 80 (3 mg), and sucrose (500 mg).",6.91028003692627,25.6092705,-0.3841201716738198,0.1201716738197424,41.54463519313304,3.829352456111448,1.7100304947949343,0.3398266795587991,0.3648068669527897,G1,Kappa,ITGA4B7,Whole mAb
vedolizumab,"ENTYVIO (VEDOLIZUMAB) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION ENTYVIO PEN (VEDOLIZUMAB) INJECTION, SOLUTION ENTYVIO (VEDOLIZUMAB) INJECTION, SOLUTION [TAKEDA PHARMACEUTICALS AMERICA, INC.]",6e94621c-1a95-4af9-98d1-52b9e6f1949c,"May 13, 2026",subcutaneous,6.5,False,,,,,,147.0,,0.0,"Each single-dose prefilled syringe or single-dose prefilled pen (ENTYVIO PEN) contains 108 mg vedolizumab, arginine hydrochloride (17.77 mg), citric acid monohydrate (0.18 mg), histidine (3.86 mg), histidine monohydrochloride (1.86 mg), polysorbate 80 (1.35 mg), sodium citrate dihydrate (4.71 mg) and Sterile Water for Injection, USP, at a pH of 6.5.",6.91028003692627,25.6092705,-0.3841201716738198,0.1201716738197424,41.54463519313304,3.829352456111448,1.7100304947949343,0.3398266795587991,0.3648068669527897,G1,Kappa,ITGA4B7,Whole mAb
zanidatamab,"ZIIHERA (ZANIDATAMAB-HRII) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [JAZZ PHARMACEUTICALS, INC.]",ae5d9425-fae5-4541-a158-150998343348,"Aug 27, 2026",intravenous,4.6,False,,,,,,124.8,,0.0,"Each single-dose vial of reconstituted product contains 300 mg of zanidatamab‑hrii and the inactive ingredients: polysorbate 20 (0.63 mg), sodium succinate (4.3 mg), succinic acid (4.3 mg), and sucrose (567 mg).",8.316437721252441,24.7553522,-0.2862831858407078,0.1371681415929203,33.73898230088496,3.5169869313385727,2.148717765465393,1.8553986267285287,0.3849557522123893,G1;G1,Kappa;Kappa,ERBB2/CD340/HER2;ERBB2/CD340/HER2,Bispecific mAb